

*This is the postprint (accepted manuscript) version of the article published by ACS in Environmental Science and Technology on December 2022. Available on-line: <https://doi.org/10.1021/ACS.EST.2C05719>*

1 **Are fish populations at risk? Metformin disrupts zebrafish development and**  
2 **reproductive processes at chronic environmentally relevant concentrations**

3  
4 Susana Barros <sup>a,b</sup>, Néelson Alves <sup>a,c</sup>, Marlene Pinheiro <sup>a,c</sup>, Marta Ribeiro <sup>a,c</sup>, Hugo Morais <sup>a,c</sup>,  
5 Rosa Montes <sup>d</sup>, Rosario Rodil <sup>d</sup>, José Benito Quintana <sup>d</sup>, Ana M. Coimbra <sup>b,e</sup>, Miguel. M.  
6 Santos <sup>a,c,\*</sup>, Teresa Neuparth <sup>a,\*,#</sup>

7 # Correspondence to: T. Neuparth, CIIMAR—Interdisciplinary Centre of Marine and Environmental Research,  
8 Endocrine Disruptors and Emerging Contaminants Group, University of Porto, Avenida General Norton de  
9 Matos, S/N, 4450-208 Matosinhos, Portugal

10 \* Corresponding author(s): [tneuparth@ciimar.up.pt](mailto:tneuparth@ciimar.up.pt) (T. Neuparth); [miguel.santos@fc.up.pt](mailto:miguel.santos@fc.up.pt) (M. M. Santos)

11 <sup>a</sup> CIIMAR—Interdisciplinary Centre of Marine and Environmental Research, Endocrine Disruptors and Emerging  
12 Contaminants Group, University of Porto, Avenida General Norton de Matos, S/N, 4450-208 Matosinhos,  
13 Portugal

14 <sup>b</sup> CITAB - Centre for the Research and Technology of Agro-Environmental and Biological Sciences, University  
15 of Trás-os-Montes and Alto Douro (UTAD), Quinta de Prados, Pavilhão 2, 5000-801 Vila Real, Portugal

16 <sup>c</sup> FCUP - Department of Biology, Faculty of Sciences, University of Porto (U. Porto), Rua do Campo Alegre s/n,  
17 4169-007 Porto, Portugal

18 <sup>d</sup> Department of Analytical Chemistry, Nutrition and Food Sciences, IAQBUS - Institute of Research on Chemical  
19 and Biological Analysis, Universidade de Santiago de Compostela, Constantino Candeira S/N, 15782 Santiago  
20 de Compostela, Spain

21 <sup>e</sup> Inov4Agro –Institute for Innovation, Capacity Building and Sustainability of Agri-food Production, Portugal

1  
2  
3  
4  
5  
6 27 **Abstract**  
7

8 28 The antidiabetic drug Metformin (MET), one of the most prevalent pharmaceuticals in the  
9 29 environment, is currently detected in surface-waters in the range of ng/L to low µg/L. As  
10 30 current knowledge regarding the long-term effects of environmentally relevant  
11 31 concentrations of MET in non-target organisms is limited, the present study aimed at  
12 32 investigating the generational effects of MET, in concentrations ranging from 390 to 14 423  
13 33 ng/L in the model organism *Danio rerio* (up to 9mpf), including the effects on its non-exposed  
14 34 offspring (until 60dpf). We integrate several apical endpoints, i.e., embryonic development,  
15 35 survival, growth and reproduction, with qRT-PCR and RNA-seq analyses to provide  
16 36 additional insights into the mode of action of MET.

17 37 Reproductive-related parameters in the first generation were particularly sensitive to MET.  
18 38 MET parental exposure impacted critical molecular processes involved in the metabolism of  
19 39 zebrafish males, which in turn affected steroid hormone biosynthesis and upregulated male  
20 40 *vtg1* expression by 99.78 to 155.47 folds at 390 and 14 432 MET treatment, respectively,  
21 41 pointing to an estrogenic effect. These findings can potentially explain the significant  
22 42 decrease in fertilization rate and the increase of un-activated eggs. Non-exposed offspring  
23 43 was also affected by parental MET exposure, impacting its survival and growth. Altogether,  
24 44 these results suggest that MET, at environmentally relevant concentrations, severely affects  
25 45 several biological processes in zebrafish, supporting the urgent need to revise the proposed  
26 46 Predicted No-Effect Concentration (PNEC) and the Environmental Quality Standard (EQS)  
27 47 for MET.

28 48

29 49 **Synopsis:** This research gathering multiple lines of evidence demonstrating that metformin,  
30 50 at environmentally relevant concentrations, severely affected important biological processes  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50


51 in zebrafish, supporting the need to revise the proposed PNEC/EQS, set several times  
52 above the concentrations tested in the present study.

53

54 **Keywords:** Contaminants of emerging concern; *Danio rerio*, Metformin full life-cycle  
55 exposure; Endocrine disruption; Risk Assessment; Water framework directive; Watch List

56

## 57 Abstract Art



58

59

## 60 1. Introduction

61 Metformin (MET), an antihyperglycemic pharmaceutical of the biguanides class, is used for  
62 the treatment of type-II diabetes mellitus (T2DM) since 2009<sup>1,2</sup>. In T2DM patients, MET acts  
63 by inhibiting the mitochondrial complex I of the electron transport chain, interfering  
64 with several metabolic pathways, such as cholesterol and steroid hormone biosynthesis<sup>3</sup>.

1  
2  
3  
4  
5  
6 65 Due to the increasing incidence of T2DM, MET is currently one of the most prescribed  
7  
8 66 human pharmaceuticals worldwide<sup>4-7</sup>. As a result, high amounts of this drug are  
9  
10 67 continuously discharged into aquatic environments. In the last decade, increasing levels of  
11  
12 68 MET were detected in surface waters, with average concentrations of 145 ng/L in Canada<sup>8</sup>,  
13  
14 69 467 ng/L in Germany<sup>9</sup> and 613 ng/L in China<sup>10</sup>. However, a recent global-scale study, that  
15  
16 70 monitored the presence of 61 pharmaceuticals along 258 rivers in 104 countries on all  
17  
18 71 continents, reported that MET is one of the top three most frequently detected  
19  
20 72 pharmaceuticals worldwide with an average concentration of 2 362.9 ng/L and extreme  
21  
22 73 concentrations detected in Tunisia (56 600 ng/L), Pakistan (51 100 ng/L) and Bolivia (46  
23  
24 74 800 ng/L)<sup>11</sup>. These studies supported the recent inclusion of MET in the 4<sup>th</sup> Watch List under  
25  
26 75 the Water Framework Directive (WFD)<sup>12</sup>, reinforcing the urgent need to get additional data  
27  
28 76 on the risk of MET for aquatic environments. Therefore, the potential risk of MET in aquatic  
29  
30 77 ecosystems should be addressed, as MET pollution can pose a serious global threat to  
31  
32 78 environmental and human health. In fact, a growing body of studies have already  
33  
34 79 investigated the effects of MET in different aquatic organisms, at different levels of biological  
35  
36 80 organization, i.e., evaluation of survival, growth and reproduction parameters in *Brachionus*  
37  
38 81 *calyciflorus*, *Daphnia similis*, *Pimephales promelas* and *Salmo trutta*<sup>13-16</sup>; endocrine  
39  
40 82 disruption in *P. promelas* and *Oryzias latipes*<sup>15,17,18</sup> and biochemical and/or gene expression  
41  
42 83 parameters in *Nothobranchius guentheri*, *P. promelas* and *O. latipes*<sup>15,17,19</sup>. In fish,  
43  
44 84 contrasting findings have been reported regarding the nature and magnitude of MET effects  
45  
46 85 associated with growth, reproduction and endocrine disruption. These divergences appear  
47  
48 86 to be related with differences in the test species used, study duration, range of tested  
49  
50 87 concentrations and exposure timing. Given the variability of effects observed following MET  
51  
52 88 exposure and considering that only a few of the aforementioned studies tested  
53  
54 89 environmentally relevant MET concentrations in long-term chronic tests, we performed a  
55  
56 90 comprehensive long-term, low-level exposure investigation with the model species *Danio*

1  
2  
3  
4  
5  
6 91 *rerio* (zebrafish), to provide further insights on MET effects in aquatic ecosystems and to  
7  
8 92 improve environmental hazard and risk assessment. This study assessed the long-term  
9  
10 93 direct effects of environmentally relevant concentrations of MET on parental ( $F_0$ ) zebrafish,  
11  
12 94 from egg to 9 months old, and the effects that MET exposure exerts on the early-life stages  
13  
14 95 of the non-exposed  $F_1$  generation (intergenerational effects). Here we combined apical  
15  
16 96 endpoints, i.e., embryonic development, survival, growth, and reproduction, with molecular  
17  
18 97 analyses, i.e., qRT-PCR and RNA-seq to provide additional insights into MET mode of action  
19  
20 98 (MoA).  
21

22 99

## 100 2. Materials and Methods

### 101 2.1. Experimental design

102 All procedures with zebrafish during the bioassay were subjected to a previous ethical review  
103 process (Supporting Information - Section S1).

104 To investigate the generational effects of environmentally relevant concentrations of MET  
105 (CAS: 1115-70-4; 98% purity; Sigma Aldrich), zebrafish were continuously exposed to three  
106 MET nominal concentrations (in duplicate): 361, 2 166, and 13 000 ng/L, plus a control group  
107 (dechlorinated tap water, in triplicate), from 4 hours post fertilization (hpf) until 9-months post  
108 fertilization (mpf) ( $F_0$ ). To evaluate the intergenerational effects of MET, the embryos  
109 resulting from  $F_0$  exposure were raised in MET-free water (control water) until reaching 60  
110 dpf –  $F_1$  (Figure 1).

111 The experiment started by randomly allocating 400 newly fertilized wild-type zebrafish  
112 embryos (4 hpf,  $F_0$ ), in 7 L aquaria. Each aquarium was maintained with a water temperature  
113 of  $28 \pm 1$  °C, a 14:10 h (light:dark) photoperiod, pH  $7.5 \pm 0.2$ , and ammonia and nitrite  
114 concentrations  $<0.04 \pm 0.02$  and  $<0.03 \pm 0.03$  mg/L, respectively. MET exposure was  
115 performed under a flow-through system using two peristaltic pumps. MET working solutions  
116 were administered at a constant flow of 4.3 mL/h using a IP peristaltic pump (ISMATEC,


1  
2  
3  
4  
5  
6 117 Germany), while clean dechlorinated, heated and charcoal filtered water was supplied at a  
7  
8 118 constant rate of 1.01 L/h using an ISM 444 peristaltic pump (ISMATEC, Germany). MET  
9  
10 119 solutions and water were pumped into a mixing chamber before being released by gravity  
11  
12 120 into aquaria<sup>20</sup>. Feeding started at 5 dpf, three times a day, with the commercial fish diet  
13  
14 121 Tetramin (Tetra, Melle, Germany) and a supplement of decapsulated *Artemia* spp cysts. Up  
15  
16 122 to 20 dpf, zebrafish larvae were fed *ad libitum* and from 20 dpf onwards, the amount and  
17  
18 123 size of food supplied were adjusted to fish development, in equal proportion for all aquaria.  
19  
20 124 At 20 dpf, animals were transferred to 30 L aquaria and fish density was reduced to 100 and  
21  
22 125 35 larvae per aquarium at 20 and 60 dpf, respectively. Thereafter, F<sub>0</sub> fish continued to  
23  
24 126 develop until 9 mpf (Figure 1).

25  
26 127 In order to evaluate MET effects on F<sub>0</sub> zebrafish reproduction, two reproductive trials were  
27  
28 128 conducted. First, a tank breeding assay was performed at 4 mpf to evaluate MET effects in  
29  
30 129 fecundity and fertilization rate, followed by a pairwise cross-breeding assay performed at  
31  
32 130 4.25 mpf to assess if potential effects were caused by maternal or paternal exposure  
33  
34 131 (detailed methodology in Supporting Information – Section S2).

35  
36 132 At 8 mpf, F<sub>0</sub> zebrafish exposed to 2 166 and 13 000 ng/L (nominal concentrations) were  
37  
38 133 reproduced to start a second generation (F<sub>1</sub>). F<sub>1</sub> embryos were raised in MET-free water  
39  
40 134 and maintained until 60 dpf, following the methodology described for F<sub>0</sub> (Figure 1).

41  
42 135 Animals were sampled several times during the bioassay, i.e., 96 hpf (F<sub>0</sub> and F<sub>1</sub> – Section  
43  
44 136 2.2), 20 dpf (F<sub>0</sub>), 60 dpf (F<sub>0</sub> and F<sub>1</sub>), and 9 mpf (F<sub>0</sub>) (Figure 1). Survival was analyzed in all  
45  
46 137 development stages, whereas total length, weight and the Fulton's condition factor  
47  
48 138  $[K=(\text{weight}/\text{length}^3)\times 100]$  were determined at 60 dpf and 9 mpf (n= 70 for MET treatments  
49  
50 139 and n=105 for control group; n=35 per replicate). Although at 60 dpf zebrafish are sexually  
51  
52 140 differentiated, the distinction between males and females was very difficult without  
53  
54 141 histological analysis. Therefore, to avoid errors in sex determination, the survival, length and  
55  
56 142 weight parameters were only measured separately for males and females at 9mpf. At 9 mpf,

143 sex ratio of each treatment was determined through direct inspection of the gonads using a  
 144 stereomicroscope (Nikon) and gonads and livers from males and females of each treatment  
 145 were excised. Gonads were weighted to calculate the gonadosomatic index [GSI=gonad  
 146 mass/body mass $\times$ 100] ( $n \approx 35$  for males and  $\approx 35$  for MET treatments and  $n \approx 52$  for males  
 147 and  $\approx 52$  females in the control group). Livers were preserved in RNALater<sup>®</sup> at  $-80^{\circ}\text{C}$  for  
 148 latter qRT-PCR and RNA-seq analyses.



152 **Figure 1.** Schematic representation of the experimental setup: exposure period, temporal scale and endpoints  
 153 analyzed in each sampling point.

## 154 155 2.2. Embryogenesis studies in F0 and F1 generations

156 Two different embryogenesis studies, with a duration of 96 h and replicated four independent  
 157 times, were conducted using different conditions: F<sub>0</sub> 96 hpf embryo assay - direct exposure  
 158 of embryos to MET, where fertilized embryos obtained from unexposed parents of our  
 159 zebrafish stock were exposed to the three MET concentrations tested in the present study,  
 160 plus control ( $n=80$ , 20 per replicate); F<sub>1</sub> 96 hpf embryo assay - indirect exposure of embryos,  
 161 where fertilized F<sub>1</sub> embryos from the 4 mpf parental exposed treatments were reared in

1  
2  
3  
4  
5  
6 162 MET-free clean water (n=80, 20 per replicate) (Figure 1). Both embryogenesis studies were  
7  
8 163 carried out using slight modifications of the OECD Fish Embryo Acute Toxicity (FET) Test  
9  
10 164 236<sup>21</sup> (detailed description in Supporting Information - Section S3).  
11  
12 165

### 14 166 2.3. MET Analytical quantification

16 167 Actual MET concentrations were determined in water samples by Liquid Chromatography-  
17  
18 168 Tandem Mass Spectrometry (LC-MS/MS). As measured concentrations were slightly  
19  
20 169 different from the nominal ones, from here onwards, a mean value of the actual MET  
21  
22 170 concentrations measured, i.e., 390, 2 929 and 14 423 ng/L, will be used rather than the  
23  
24 171 nominal ones (detailed description in Supporting Information – Section S4, Table S1).  
25  
26 172

### 28 173 2.4. F<sub>0</sub> Gene expression after 9 months of MET exposure

#### 30 174 2.4.1. RNA isolation

32 175 At F<sub>0</sub> 9mpf, RNA from livers was individually isolated from 12 males and 12 females of each  
33  
34 176 treatment via Illustra RNAspin Mini RNA Isolation Kit (GE Healthcare), according to the  
35  
36 177 manufacturer's protocol. Quantification of isolated RNA was performed in a Take 3 Micro-  
37  
38 178 Volume Plate Reader (Biotek Synergy HT) coupled with Gen5 (version 2.0). RNA quality  
39  
40 179 was verified by 1.5% agarose gel electrophoresis and by  $\lambda_{260}/\lambda_{280}$  nm absorbance ratio.  
41  
42 180

#### 44 181 2.4.2. Fluorescence based quantitative real-time PCR (qRT-PCR) 46 182 analysis

48  
49 183 To evaluate the effects of MET at the molecular level, qRT-PCR was used in 8 males and 8  
50  
51 184 females liver samples from all MET treatments (390, 2 929 and 14 423 ng/L) and from the  
52  
53 185 control group to quantify the transcription profiles of vitellogenin encoding genes, i.e. *vtg1*  
54  
55 186 and *vtg2*, which are essential for egg production and a marker of estrogenicity. The  
56  
57 187 ribosomal protein L 13 gene (*rp13*) was selected as a housekeeping gene. Details of the  
58  
59  
60

1  
2  
3  
4  
5  
6 188 rational for genes selection and primers design is described in Supporting Information –  
7  
8 189 Section S5, Table S2 and qRT-PCR methodology in Section S6.  
9

10 190

#### 11 191 2.4.3. Liver RNA-seq analysis

12  
13  
14 192 To gain further insights into the canonical pathways affected by MET beyond the findings of  
15  
16 193 the exploratory RNA-seq analysis presented in our parallel study<sup>3</sup>, we performed a more  
17  
18 194 detailed transcriptomic analysis with biological replication focusing on zebrafish liver using  
19  
20 195 3-4 independent pools, composed by 3 individually extracted RNA livers, from the control  
21  
22 196 and 3 livers from the 14 432 ng/L MET treatment for each sex (n=3-4). This RNA-seq  
23  
24 197 approach, commercially obtained at Novogene (United Kingdom), was used to perform a  
25  
26 198 mechanistic analysis on the genes and pathways involved in steroid biosynthesis and  
27  
28 199 reproductive processes and to validate the genes/pathways related with energy/lipid  
29  
30 200 metabolisms found to be altered in the exploratory RNA-seq analysis of our parallel study<sup>3</sup>.  
31  
32 201 Samples were subjected to sequencing (Illumina Novaseq 6000 paired-end (2x150)) and  
33  
34 202 subsequent bioinformatics analysis with parameters set to: false discovery rate (FDR) p-  
35  
36 203 value (padj)<0.05 and a  $\text{Log}_2(\text{FoldChange})>0$ . Raw data was submitted to the NCBI SRA  
37  
38 204 database under the BioProject PRJNA906165. Detailed methodology is described in  
39  
40 205 Supporting Information - Section S7.  
41

42 206

#### 43 207 2.5. Statistical analysis

44  
45  
46 208 All statistical analyses were computed with Statistica 12.5 (Statsoft, USA). Obtained data  
47  
48 209 was checked for normality and homogeneity of variances, using Kolmogorov-Smirnov and  
49  
50 210 Levene's tests. Data were then analyzed by one-way ANOVA, and Post-hoc comparisons  
51  
52 211 using Fisher's least significant difference (LSD) test. Significant differences were set as  
53  
54 212  $p<0.05$ .  
55

56 213

### 214 3. Results and Discussion

215 Despite the ubiquitous presence of MET in aquatic ecosystems, uncertainties still remain  
216 about its long-term effects on non-target organisms. Therefore, in order to fill the knowledge  
217 gaps on the effects of environmentally relevant concentrations of MET in aquatic  
218 environments, the present study implemented a long-term multi-endpoint approach focusing  
219 on different zebrafish developmental stages to address direct effects of MET on parental  
220 exposed organisms ( $F_0$ ) and the effects that parental exposure exerts on indirectly exposed  
221 generations [intergenerational effects ( $F_1$ )].

#### 222 3.1. $F_0$ and $F_1$ Survival

223 First, we evaluated the effects of MET on survival of different developmental stages of  
224 zebrafish [i.e., larvae (96 hpf and 20 dpf), juveniles (60 dpf) and adults (9 mpf)] in the  
225 exposed  $F_0$  generation; and in the indirectly exposed larvae (96 hpf) and juveniles (60 dpf)  
226 from the  $F_1$  generation (Table 1). In the direct MET exposure ( $F_0$ ), we found a significant  
227 decrease in survival on 96 hpf larvae at MET concentrations as low as 390 ng/L. At 20 dpf,  
228 a significant decrease in survival was also observed for larvae exposed to 2 929 and 14 423  
229 ng/L of MET, when compared to control (45.2 and 24.4% survival, respectively) (Table 1).  
230 As expected, after 20 dpf mortality was very low until adulthood, since even under normal  
231 raising conditions, zebrafish are more sensitive up to 20 dpf, considering that during this  
232 period they develop from one cell stage into a swimming larva and change from vitellogenic  
233 reserves to external feeding<sup>20,22</sup>. Other recent studies with zebrafish are in agreement with  
234 the present findings, reporting that MET at concentrations from 1 to 10  $\mu\text{g/L}$  significantly  
235 impacts zebrafish survival at the early phases of development<sup>23,24</sup>. However, these effects  
236 in mortality are not supported by other studies examining the effects of MET in other fish  
237 species, such as brown trout (*Salmo trutta*) and fathead minnows (*Pimephales promelas*),  
238 where MET exposure did not impact mortality at different development phases, including the

larval stage<sup>16,25,26</sup>. Analyzing the few available studies, we hypothesize that zebrafish, at least in the early-life stages of development, are potentially more sensitive than the other few fish species tested so far that present longer periods of embryonic development. Together with the decreased survival in F<sub>0</sub> larvae, this parameter was also significantly impacted in F<sub>1</sub> 96 hpf larvae (Table 1). Thus, the effects of MET exposure experienced by F<sub>0</sub> zebrafish during its lifetime led to decreased survival in the early stages of the non-directly exposed generation (F<sub>1</sub>). Importantly, the decrease in larvae survival in both F<sub>0</sub> and F<sub>1</sub>, at environmentally relevant MET concentrations, raises concerns on the potential effects in the recruitment and population fitness of the most sensitive fish species in aquatic ecosystems.

**Table 1.** Effects of MET on survival (%) of *D. rerio* from F<sub>0</sub> and F<sub>1</sub> generations. Data expressed as mean ± standard error. Significant differences are highlighted in bold and with asterisks (\*) (p<0.05). Cardinals (#) indicate differences with p<0.1.

Treatment	Survival (%)				F1 96 hpf <sup>a</sup>	F1 60 dpf <sup>b</sup>
	F0 96 hpf <sup>a</sup>	F0 20 dpf <sup>b</sup>	F0 60 dpf <sup>b</sup>	F0 9 mpf <sup>b</sup>		
Control	95.8 ± 1.70	83.7 ± 3.10	91.0 ± 5.00	98.2 ± 1.79	83.3 ± 6.13	98.0 ± 1.00
390 ng/L	<b>75.6* ± 4.79</b>	52.4 ± 9.20 <sup>#</sup>	71.0 ± 10.00	100.0 ± 0.00	76.0 ± 6.88	N.A.
2 929 ng/L	85.6 <sup>#</sup> ± 3.41	<b>45.2 ± 12.20*</b>	89.5 ± 3.50	95.8 ± 1.25	87.5 ± 3.80	99.0 ± 0.00
14 423 ng/L	<b>74.4* ± 3.93</b>	<b>24.4 ± 11.60*</b>	87.0 ± 1.00	95.2 ± 1.07	<b>61.4* ± 2.78</b>	97.0 ± 2.00

a – Data obtained from embryogenesis studies

b – Data obtained from generational exposure study

N.A. – Data not available

Note – Data from generational exposure is presented for each stage of development: 20 dpf represents the data between 4 hpf and 20 dpf; 60 dpf represents the data between 20 dpf and 60 dpf, and 9 mpf represents the data between 60 dpf and 9 mpf

### 3.2. F<sub>0</sub> and F<sub>1</sub> growth effects

Zebrafish growth parameters were also affected in F<sub>0</sub> and F<sub>1</sub>. The F<sub>0</sub> zebrafish larvae (96 hpf), exposed to 2 929 ng/L of MET, were significantly smaller than the control group (Table 2). However, an opposite pattern in the juvenile phase (F<sub>0</sub> 60 dpf) was detected, with an increase in length, weight and overall body condition factor (K) observed in the 390 ng/L MET treatment (Table 2). This trend continued until adulthood, where F<sub>0</sub> 9 mpf males exposed to the highest MET concentration (14 423 ng/L), were significantly bigger and

1  
2  
3  
4  
5  
6 266 heavier than control males. Additionally, males and females exposed to 2 929 and 14 423  
7  
8 267 ng/L, respectively, displayed a significantly higher K. It should be noted that the significant  
9  
10 268 increase in growth parameters observed for 60 dpf and 9 mpf zebrafish exposed to MET  
11  
12 269 cannot be linked with higher food availability in exposed treatments due to the mortality  
13  
14 270 observed in early phases. In fact, until 20 dpf, zebrafish larvae were fed *ad libitum* to ensure  
15  
16 271 that all treatment larvae had equal food access to properly survive and grow; after 20 dpf  
17  
18 272 (i.e., at 20 and 60 dpf), when the mortality was very low until adulthood, the number of fish  
19  
20 273 and food were equally adjusted in all aquaria.

21  
22 274 The growth findings here presented suggest that MET exposure impacted zebrafish  
23  
24 275 differently, depending on the concentration tested, but also on the development stage of  
25  
26 276 zebrafish, i.e., larvae, juvenile, and adult, with larvae exposed to MET being significantly  
27  
28 277 smaller and juveniles and adults larger, heavier and with a higher K. Likewise, the studies  
29  
30 278 available in literature addressing the potential impacts of MET show that the nature of the  
31  
32 279 effects induced by MET on fish growth, reproduction and endocrine functions appear to differ  
33  
34 280 depending on the species and developmental stage, study duration and tested  
35  
36 281 concentrations. However, most of these studies are based in short partial life-cycle  
37  
38 282 exposures, focus on one developmental stage (mainly early development phases) and  
39  
40 283 present mixed results. For example, 28-day and 57-day MET exposures at concentrations  
41  
42 284 of 1-100 µg/L and 1 µg/L have shown to induce decreased weight and length in early life  
43  
44 285 stages of the Japanese medaka (*Oryzias latipes*)<sup>18</sup> and *S. trutta*<sup>16</sup>, respectively. Yet, an  
45  
46 286 increase in length or no effects on growth parameters were observed when embryos/larvae  
47  
48 287 of fathead minnow (*P. promelas*) were exposed to similar MET concentrations for 5<sup>27</sup> or 21  
49  
50 288 days<sup>26</sup>, respectively. A similar increase in length was reported for *P. promelas* larvae  
51  
52 289 exposed to 31 µg/L of MET at day 30 and an increase of the condition factor after MET  
53  
54 290 exposure of 322 µg/L at day 64<sup>25</sup>.

1  
2  
3  
4  
5  
6 291 Ideally, chronic studies should test environmentally relevant concentrations of chemicals  
7  
8 292 and cover the entire life-cycle of the tested organism(s), in order to mimic the real case  
9  
10 293 scenarios of wild populations<sup>3,22,28–30</sup>, which is what we aimed at the present study. However,  
11  
12 294 the studies available in the literature that assess the full life-cycle effects of environmentally  
13  
14 295 relevant concentrations of MET in different fish developmental stages are scarce. Beyond  
15  
16 296 the present research, Ussery et al. (2018)<sup>18</sup> and Parrott et al. (2021)<sup>25</sup> studies have reported  
17  
18 297 growth decrease in early life stages of *O. latipes* and *P. promelas* exposed to 3.2 and 31  
19  
20 298 µg/L of MET respectively, but no effects were visible at adulthood, after approximately 200  
21  
22 299 days. Additionally, Niemuth and Klapper (2015)<sup>15</sup> reported a decrease in weight and body  
23  
24 300 condition factor in adult males of *P. promelas* following a 365-day exposure to 40 µg/L of  
25  
26 301 MET. These findings contrast with the increased growth parameters reported in the present  
27  
28 302 study at the juvenile and adult stages. We cannot exclude the possibility that the Ussery et  
29  
30 303 al. (2018) study<sup>18</sup> failed to observe effects on growth of *O. latipes*, as only one concentration  
31  
32 304 was tested at adulthood (3.2 µg/L). On the other hand, the MET concentrations tested in the  
33  
34 305 studies of Parrott et al. (2021)<sup>25</sup> and Niemuth and klapper (2015)<sup>15</sup> were much higher than  
35  
36 306 those tested in the present study and above ecological relevance, which could justify the  
37  
38 307 contrasting results. We hypothesize that the stimulating effects on zebrafish growth  
39  
40 308 parameters (length, weight and K), observed at 60 dpf and 9 mpf, by environmentally  
41  
42 309 relevant concentrations of MET, could be associated with a phenomenon called hormesis.  
43  
44 310 Hormesis is an adaptive response well documented in aquatic organisms in response to  
45  
46 311 long-term exposure to low concentrations of a variety of environmental stressors<sup>31,32</sup>, that  
47  
48 312 results from an overcompensation of the homeostatic regulatory mechanisms, leading to  
49  
50 313 stimulatory effects (e.g., improved growth and/or reproduction)<sup>31,33,34</sup>. This hormesis  
51  
52 314 phenomenon induced by MET was also suggested by Elizalde-Velazquez et al. (2021)<sup>24</sup> in  
53  
54 315 early developmental phases of zebrafish. Despite the potential hormetic effect here  
55  
56 316 observed in zebrafish growth and weight (F<sub>0</sub> 60 dpf and 9 mpf males), other key ecological

317 endpoints revealed severe signs of toxicity, such as increased mortality at early stages of  
 318 development and disruption of reproductive processes (discussed in sections 3.1 and 3.3).  
 319 Growth was also affected in the F<sub>1</sub> generation. A significant length increase was observed  
 320 in F<sub>1</sub> 96 hpf larvae for all MET treatments, and in F<sub>1</sub> 60 dpf juveniles for the 2 929 ng/L MET  
 321 concentration (Table 2). This increase in length in the F<sub>1</sub> 60 dpf juveniles, which was  
 322 accompanied by a decrease of K in all MET treatments, shows that F<sub>1</sub> zebrafish were gaining  
 323 less weight in proportion to their size. These results highlight the impacts of MET in F<sub>1</sub> early  
 324 stages of development, even in the absence of direct exposure, which can potentially be  
 325 linked with epigenetic modifications. In fact, our RNA-seq analysis (section 3.3.2) showed  
 326 several differentially expressed genes involved in epigenetic modification in both males  
 327 (e.g., *piwil2*, *tdrd9*, *prdm12b*, *znf541* and *mcm8*) and females (e.g., *dnmt1*, *uhrf1* and  
 328 *suv39h1a*) (Supporting information – Table S8). This hypothesis is further supported by  
 329 previous studies using mammalian and cancer cell lines that have shown that MET affects  
 330 DNA methylation<sup>35–37</sup>, histone modifications<sup>35,38,39</sup> and microRNAs<sup>40–42</sup>. The observations  
 331 here reported are of particular concern from an environmental risk assessment perspective  
 332 as MET adverse effects at environmental relevant concentrations are potentially passed to  
 333 future generations. As such, future research is needed to uncover the potential molecular  
 334 mechanisms underlying MET modulation of epigenetic markers and how these relate with  
 335 the effects here reported.

336

337 **Table 2.** Effects of MET on sex ratio, weight, length, Fulton's condition factor (K) and gonadosomatic index (GSI)  
 338 of *D. rerio* from F<sub>0</sub>, F<sub>1</sub> generations (M, males; F, females; N.A., not-measured). Data expressed as mean ±  
 339 standard error. Significant differences are highlighted in bold and with asterisks (\*) (p<0.05). Cardinals (#)  
 340 indicate differences with p<0.1

Generation	Sampling Time	Treatment	Sex ratio (M:F) %	Weight (mg)	Length (mm)	K	GSI
<b>F<sub>0</sub></b>	96 hpf	Control	N.A.	N.A.	3.91 ± 0.0206	N.A.	N.A.

14

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

		390 ng/L	N.A.	N.A.	3.86 ± 0.0192 <sup>#</sup>	N.A.	N.A.				
		2 929 ng/L	N.A.	N.A.	<b>3.84 ± 0.0138*</b>	N.A.	N.A.				
		14 423 ng/L	N.A.	N.A.	3.90 ± 0.0171	N.A.	N.A.				
		Control	N.A.	19.79 ± 1.963	1200.00 ± 31.000	0.80 ± 0.022	N.A.				
	60 dpf	390 ng/L	N.A.	<b>28.49 ± 4.253*</b>	<b>1380.00 ± 60.000*</b>	<b>0.92 ± 0.071*</b>	N.A.				
		2 929 ng/L	N.A.	23.59 ± 1.786	1310.00 ± 35.000	0.85 ± 0.020	N.A.				
		14 423 ng/L	N.A.	22.67 ± 4.389	1300.00 ± 74.000	0.78 ± 0.023	N.A.				
				M	F	M	F	M	F		
		Control	56.50 : 43.50	510.30	749.00	3760.00	4050.00	0.94	1.12	0.84	11.48
			±	±	±	±	±	±	±	±	±
			5.010	24.730	29.510	70.000	49.000	0.037	0.034	0.110	0.867
		390 ng/L	56.00 : 44.00	546.30	832.50	3860.00	4120.00	0.94	1.16	0.65	14.17
			±	±	±	±	±	±	±	±	±
			21.180	13.230	45.110	32.000	69.000	0.016	0.035	0.085	1.777
		2 929 ng/L	62.60 : 37.40	551.50	819.60	3800.00	4140.00	<b>1.02</b>	1.15	0.83	12.26
			±	±	±	±	±	±	±	±	±
			1.710	15.690	40.250	61.000	48.000	<b>0.033*</b>	0.032	0.074	1.273
		14 423 ng/L	55.90 : 44.10	<b>609.80</b>	848.90	<b>3970.00</b>	4070.00	0.97	<b>1.25</b>	0.97	15.59
			±	±	±	±	±	±	±	±	±
			4.070	<b>20.940</b>	37.340	<b>40.000*</b>	55.000	0.035	<b>0.037*</b>	0.103	1.896
				*							
		Control	N.A.	N.A.	3.90 ± 0.0142	N.A.	N.A.				
		390 ng/L	N.A.	N.A.	<b>3.99 ± 0.0160*</b>	N.A.	N.A.				
	96 hpf	2 929 ng/L	N.A.	N.A.	<b>4.09 ± 0.0208*</b>	N.A.	N.A.				
		14 423 ng/L	N.A.	N.A.	<b>4.07 ± 0.0200*</b>	N.A.	N.A.				
		Control	N.A.	13.51 ± 0.812	1190.00 ± 26.000	0.73 ± 0.018	N.A.				
	60 dpf	2 929 ng/L	N.A.	15.25 ± 0.666	<b>1290.00 ± 23.000*</b>	<b>0.68 ± 0.013*</b>	N.A.				
		14 423 ng/L	N.A.	13.97 ± 1.057	1230.00 ± 35.000	<b>0.70 ± 0.016*</b>	N.A.				

F<sub>1</sub>

341

342

343

### 3.3. F<sub>0</sub> Reproductive processes

344 In order to further disentangle the effects of MET in apical endpoints, we then focused on  
 345 the potential effects of MET on zebrafish reproduction using breeding studies to assess the  
 346 reproductive output and q-PCR/RNA-seq analyses to evaluate the expression of gene  
 347 networks involved in endocrine processes.

15

1  
2  
3  
4  
5  
6 3487  
8 349 3.3.1. Reproductive success

9  
10 350 The results of the two F<sub>0</sub> reproductive studies are presented in Table 3. In the tank breeding  
11 351 approach, (tanks holding a number of males and females that replicate the treatment sex  
12 352 ratio), the reproductive success of F<sub>0</sub> 4 mpf, indicates that no MET treatment affected  
13 353 fecundity or fertilization rates. However, this breeding approach can potentially increase data  
14 354 variability and may not allow sufficient statistical power to fully assess the fecundity rate,  
15 355 since this approach doesn't determine how many males and females contributed to eggs  
16 356 spawned at each reproductive event. Although both fecundity and fertilization rates weren't  
17 357 affected, a dose-dependent significant increase of un-activated eggs was recorded for all  
18 358 MET treatments compared to control. Furthermore, reproductive events with un-activated  
19 359 eggs were observed at all MET treatments, but not in the control group (Table 3, Supporting  
20 360 information - Figure S1). In zebrafish, eggs are activated once they come in contact with  
21 361 water<sup>43</sup>. The egg activation process is characterized by the expansion and hardening of the  
22 362 chorion, which is essential for egg fertilization and development, as it prevents polyspermy  
23 363 and creates a protective barrier for the developing embryo<sup>43,44</sup>.

24 364 In order to clarify if the presence of un-activated eggs was due to reproductive disruption on  
25 365 males or females exposed to MET, a second reproductive study was performed in the F<sub>0</sub>  
26 366 4.25 mpf zebrafish, using a pairwise cross-breeding approach (one male X one female).  
27 367 This second reproductive study was conducted between fish from the control and from the  
28 368 highest MET concentration (14 423 ng/L), using three different combinations, i.e., males and  
29 369 females from control ( $\text{♂}_{\text{Ctrl}} \times \text{♀}_{\text{Ctrl}}$ ) or males/females from the 14 423 ng/L MET concentration  
30 370 with control animals ( $\text{♂}_{14\ 423\ \text{MET}} \times \text{♀}_{\text{Ctrl}}$  and  $\text{♂}_{\text{Ctrl}} \times \text{♀}_{14\ 423\ \text{MET}}$ ) (Table 3). Interestingly, the  
31 371 results show a significant decrease in the fertilization rate ( $p < 0.05$ ), a tendency for lower  
32 372 fecundity ( $p = 0.08$ ) and the presence of un-activated eggs only in the breeding pairs with  
33 373 exposed males (Table 3). These findings indicate that the reproductive capability of males

54  
55  
56  
57  
58  
59 16  
60

1  
2  
3  
4  
5  
6 374 was particularly affected by MET, and that pairwise breeding is a better approach than tank  
7  
8 375 breeding to assess zebrafish reproductive output, as it yields better statistical power.  
9  
10 376 Although short-term reproductive studies with adult *P. promelas* exposed in pairs failed to  
11  
12 377 show MET disruption in fish reproduction<sup>45,46</sup>, these studies may not represent the full effects  
13  
14 378 of environmental exposure, since the critical period of sexual differentiation was not included  
15  
16 379 in the exposure. Despite the short-term reproductive studies referenced above, the  
17  
18 380 assumption that pairwise breeding is a better alternative to the tank breeding approach to  
19  
20 381 assess MET effects in fish reproductive success is largely in agreement with the two full life-  
21  
22 382 cycle studies that addressed the reproductive output of *P. promelas* exposed to MET<sup>15,25</sup>.  
23  
24 383 Even though Parrot et al. (2021)<sup>25</sup> failed to find MET adverse effects in the reproductive  
25  
26 384 success of *P. promelas* using a method similar to our tank breeding approach, Niemuth and  
27  
28 385 Klapper (2015)<sup>15</sup> observed decreased fecundity in MET exposed fish with a pairwise  
29  
30 386 breeding approach. Thus, based on the available full life-cycle data (ours and Niemuth and  
31  
32 387 Klapper (2015)<sup>15</sup>), MET appears to affect the reproductive output of model fish.  
33  
34 388 Most available studies, in different *taxa*, largely associate reproductive output alterations  
35  
36 389 induced by contaminants with maternal transmission<sup>44</sup>. However, in the case of MET, our  
37  
38 390 findings show that male exposure history negatively impacts reproductive performance of  
39  
40 391 zebrafish. Previous studies in zebrafish have described that male sex pheromones are  
41  
42 392 essential for a successful reproduction due to its role in female attraction, triggering ovulation  
43  
44 393 and oviposition<sup>47-49</sup>. Moreover, it is also known that male sex pheromones influence the  
45  
46 394 quality and viability of embryos<sup>48</sup>. The absence of male pheromones at the time of  
47  
48 395 reproduction results in egg spawning lacking chorion expansion, i.e., un-activated eggs<sup>48</sup>. A  
49  
50 396 significant part of male pheromones are glucuronidated conjugates of steroid sex  
51  
52 397 hormones<sup>50</sup>, which have been shown to be modulated by MET, as part of its putative  
53  
54 398 MoA<sup>1,4,51,52</sup> (this mechanism is further discussed in section 3.3.2 based on the qRT-PCR and  
55  
56 399 RNA-seq data obtained in the present study).

400

401 **Table 3.** Chronic effects of MET on F<sub>0</sub> zebrafish tank breeding and pairwise cross-breeding (Comparison  
 402 between control and MET 14 423 ng/L). Data on fecundity (number of embryos/female/day), % of fertilization (%  
 403 of fertilized eggs/female/day), % reproductive events with un-activated eggs, and % of un-activated eggs (n=10  
 404 reproductive events of *D. rerio* at 4 mpf). Data expressed as mean ± standard error. Significant differences are  
 405 highlighted in bold and asterisks (\*) (p<0.05). Cardinals (#) indicate p<0.1.


		Fecundity	% Fertilization	% of reproductive events with un-activated eggs	% un-activated eggs/reproductive event
Tank breeding	Control	45.1 ± 3.80	93.3 ± 0.90	0.0 ± 0.00	0.0 ± 0.00
	MET = 390 ng/L	52.2 ± 4.40	92.0 ± 1.30	<b>29.0 ± 7.00*</b>	<b>2.5 ± 1.24*</b>
	MET = 2 929 ng/L	68.1 ± 3.30	96.7 ± 0.40	<b>56.0 ± 13.00*</b>	<b>3.5 ± 0.97*</b>
	MET = 14 423 ng/L	75.0 ± 10.80	89.8 ± 1.40	<b>73.0 ± 14.00*</b>	<b>7.4 ± 3.62*</b>
Pairwise cross-breeding	♂ <sub>Ctrl</sub> X ♀ <sub>Ctrl</sub>	286.4 ± 22.70	98.1 ± 0.70	0.0 ± 0.00	0.0 ± 0.00
	♂ <sub>14 423</sub> X ♀ <sub>Ctrl</sub>	198.8 ± 62.90 <sup>#</sup>	<b>88.5 ± 4.10*</b>	<b>56.0 ± 5.77*</b>	<b>22.6 ± 5.33*</b>
	♂ <sub>Ctrl</sub> X ♀ <sub>14 423</sub>	226.9 ± 39.70	97.2 ± 0.80	0.0 ± 0.00	0.0 ± 0.00

406

407

### 408 3.3.2. qRT-PCR and RNA-seq

409 Considering the findings obtained in the reproductive assays, that point to reproductive  
 410 changes linked to males, and previous studies indicating that MET can potentially act as an  
 411 endocrine-disrupting chemical in fish by increasing expression of estrogen associated  
 412 vitellogenin (VTG) encoding genes in males<sup>15,17,53</sup>, we further evaluated the effects of MET  
 413 at the molecular level. First, a strong focus was given to a liver q-PCR screening of  
 414 expression of the *vtg1* and *vtg2* genes for all treatments. We found that, in males, *vtg1* was  
 415 particularly altered with a significant increase in all MET treatments (fold inductions from  
 416 99.78 for 390 ng/L MET to 155.47 for 14 423 ng/L MET) and *vtg2* mRNA levels were also  
 417 significantly upregulated by 8.28 and 8.80-fold, in 2 929 ng/L and 14 423 ng/L MET  
 418 treatments, respectively (Figure 2.B). In females, *vtg1* showed a significant upregulation with  
 419 a low fold induction of 1.8 for the lowest MET concentration tested (390 ng/L) and *vtg2* was  
 420 significantly downregulated by 2.09-fold for 14 423 ng/L MET treatment (Figure 2.A).



421

422 **Figure 2.** *F*<sub>0</sub> *D. rerio* liver mRNA levels of *vtg1* and *vtg2* relative to *rpl13*, after 9-months exposure to MET in both  
 423 females (A) and males (B). Error bars indicate standard errors; asterisks indicate significant differences from de  
 424 control group (1-fold) (\*-  $p < 0.05$ ; \*\*-  $p < 0.01$ ; \*\*\*-  $p < 0.001$ ) ( $n = 6-8$ ).

425

426 As VTG is typically synthesized as an egg yolk precursor<sup>54,55</sup>, high levels of VTG or mRNA  
 427 levels of its encoding genes (*vtg*) in males have been used over the years as a marker of  
 428 endocrine disruption associated with estrogenic compounds<sup>20,56,57</sup>. Of concern is the 99-fold  
 429 increase of *vtg1* here induced by 390 ng/L of MET in males' liver, more than double when  
 430 compared to a 40-fold induction in male zebrafish exposed to 2 ng/L of ethinylestradiol, a  
 431 well-known and potent estrogenic endocrine disrupting compound<sup>20</sup>. This 99-fold induction  
 432 points to a severe feminizing effect of MET at concentrations as low as 390 ng/L. Previous  
 433 studies have reported that MET exposure was able to modulate the expression of male *vtg*  
 434 genes in other fish species, although at higher concentrations and much lower fold  
 435 induction<sup>17,46,58</sup>. Since MET is commonly detected in surface waters worldwide in  
 436 concentrations at the same range of those tested in this study or even higher<sup>8,9,59-61</sup>, this

19

1  
2  
3  
4  
5  
6 437 data suggests that freshwater ecosystems are facing massive chemical loads with the  
7  
8 438 capability to trigger estrogenic responses, despite global efforts to decrease the  
9  
10 439 estrogenicity of river waters<sup>62–64</sup>. Nonetheless, the MoA by which MET can upregulate *vtg1*  
11  
12 440 and *vtg2* gene expression is still unclear. Since MET does not have a hormone-like structure,  
13  
14 441 a direct disruption of estrogen receptors (ERs) is therefore unlikely. Furthermore, the  
15  
16 442 interaction of MET with transcription factors, such as retinoic acid receptor (*RAR*) or  
17  
18 443 peroxisome proliferator-activated receptor gamma (*PPAR $\gamma$* ), previously indicated to bind to  
19  
20 444 retinoic acid responsive elements (RARE) in the promoter region of *vtg1* and *vtg2* for  
21  
22 445 regulate their gene expression<sup>55</sup>, are also unlikely. The RNA-seq analysis performed here  
23  
24 446 and discussed below, showed no changes in the expression levels of *pparg* and *rar* genes  
25  
26 447 nor in the downstream pathways regulated by these nuclear receptors (Supporting  
27  
28 448 information – Table S3). Instead, it is hypothesized that MET may regulate VTG synthesis  
29  
30 449 by modulating steroid biosynthesis<sup>46,58,59,65</sup>, although future studies should demonstrate the  
31  
32 450 detailed mechanism associated with VGTs induction.

33  
34 451 To provide additional insight into the MoA of MET, we looked more closely for gene networks  
35  
36 452 related with energy/lipid metabolism signaling, steroid hormone biosynthesis and  
37  
38 453 reproductive processes, that can potentially be involved in the proposed estrogenic activity  
39  
40 454 of MET in males. Thus, a comprehensive transcriptome analysis with biological replication  
41  
42 455 was produced for liver samples of males and females from the control group and from the  
43  
44 456 14 423 ng/L MET treatment (Supporting information – Table S3 and S4) to strengthen the  
45  
46 457 data of our previous exploratory RNA-seq analysis<sup>3</sup>. Importantly, the hierarchical clustering  
47  
48 458 heatmap (Supporting Information – Figure S3) reported that exposed males presented a  
49  
50 459 pattern of gene expression closer to the females (MET exposed and control) than to the  
51  
52 460 control males. Furthermore, the RNA-seq findings showed multiple metabolic processes  
53  
54 461 significant disrupted in males. A total of 121 genes were found to be differentially expressed,  
55  
56 462 with 61 downregulated (e.g., *nme9*, *insl3*, *insl5b* *gpat2* – energetic metabolism and *fabp6*,

1  
2  
3  
4  
5  
6 463 *lrp2b* – lipid metabolism) and 60 upregulated (e.g., *cox5ab*, *pkmb* – energetic metabolism  
7  
8 464 and *nr2f5*, *ebpl*, *ckmb*, *hadhaa* – lipid metabolism) (Supporting information – Table S5),  
9  
10 465 which correlates well with the metabolic changes observed in our parallel study, both at  
11  
12 466 molecular and biochemical levels<sup>3</sup>. Moreover, 3 steroidogenic genes, essential for the  
13  
14 467 production of sex hormones, were found to be downregulated (*cyp11c1*, *cyp17a1* and *star*)  
15  
16 468 and one upregulated (*ugt2a7*) (Supporting information – Table S5). The down regulation of  
17  
18 469 *star*, a key rate-limiting enzyme of steroid hormones synthesis, together with *cyp11c1*,  
19  
20 470 *cyp17a1*, could indicate a disruption of the homeostatic regulation of steroids<sup>66</sup>. These  
21  
22 471 findings are also in agreement with the significant decrease in cholesterol levels in the livers  
23  
24 472 of MET exposed males reported in our parallel study<sup>3</sup>, as cholesterol is the sole precursor  
25  
26 473 of steroid hormones<sup>67,68</sup>, and is also associated with the upstream deregulation of genes  
27  
28 474 coding energy/lipid metabolism processes. Finally, we noted 49 downregulated genes linked  
29  
30 475 to reproductive processes, most of them involved in gametogenesis/sex differentiation (e.g.,  
31  
32 476 *amh*, *ddx4*, *dmrt1*, *piwil1* and *spata4*) and sperm motility (e.g., *dnaah1*, *dnai1.1*, *dnaaf2* and  
33  
34 477 *spef1*) (Supporting information – Table S5). Although these reproductive genes are often  
35  
36 478 associated with gonads, they also express in the liver of control animals, albeit with lower  
37  
38 479 transcript levels<sup>69–73</sup>. Interestingly, although our reproductive trials did not find any effects  
39  
40 480 associated with females, a large number of genes associated with energy/lipid metabolism  
41  
42 481 signaling, steroid hormone biosynthesis and reproductive processes were also observed to  
43  
44 482 have a differential gene expression between control and MET exposed females. This  
45  
46 483 suggests that several females signaling pathways could also be disrupted by MET  
47  
48 484 (Supporting information – Table S6).  
49  
50 485 Focusing more broadly on Protein-Protein Interaction (PPI) and in the Gene ontology (GO)  
51  
52 486 enrichment analyses (Supplementary information - Section S8, Figure S3 and Table S7),  
53  
54 487 several categories of gene networks were identified in males exposed to MET, showing  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 488 further evidence that MET disrupts zebrafish reproduction by dysregulating its lipid/energy  
7  
8 489 metabolism, in turn affecting steroid hormone biosynthesis pathways.

9  
10 490 Taken together the findings of the present study with those of our parallel study<sup>3</sup>, MET  
11  
12 491 appears to deregulate critical biochemical and molecular processes in male zebrafish  
13  
14 492 metabolism, which in turn could affect the steroid hormone biosynthesis and the expression  
15  
16 493 of *vtg1* and *vtg2*. We hypothesize that this disruption can be linked with the significantly  
17  
18 494 decreased in the fertilization rate and the non-activated eggs reported in the pairwise cross-  
19  
20 495 breeding study.

21  
22 496

#### 23 24 497 3.4. Final Remarks and Implications for Hazard and Risk Assessment

25  
26  
27 498 According to the available data, the impact of MET in non-target organisms is not fully  
28  
29 499 consistent among studies regarding the effects of MET on fish growth, reproduction and/or  
30  
31 500 endocrine functions. These differences can reflect the limited number of studies performed  
32  
33 501 so far and the use of distinct experimental designs, i.e., different MET concentrations  
34  
35 502 evaluated, different test species and study duration. Apart from the present work, there is a  
36  
37 503 paucity of data assessing long-term effects of environmentally relevant concentrations of  
38  
39 504 MET in different time-points during fish life cycle. Most of the studies available tested MET  
40  
41 505 concentrations above those reported in surface waters, and/or fish were exposed for short  
42  
43 506 time-periods, covering only one stage of the life cycle<sup>25,27,53,74</sup>.

44  
45 507 In fact, there are still significant gaps in our understanding of the ecological impacts of MET  
46  
47 508 in fish. However, our findings, together with previous studies, provide strong evidence that  
48  
49 509 current MET concentrations in aquatic environments may be sufficient to disrupt survival,  
50  
51 510 growth, reproduction and metabolic/endocrine functions of fish. Putting together the multiple  
52  
53 511 lines of evidence addressed in the present study, MET, at environmentally relevant  
54  
55 512 concentrations, impacted several biological processes in zebrafish. A concentration as low  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 513 as 390 ng/L of MET was able to affect early life stages of zebrafish in F<sub>0</sub> and F<sub>1</sub> generations,  
7  
8 514 disrupt growth throughout its life cycle, impair reproductive output and massively induce *vtg1*  
9  
10 515 gene expression in males. Furthermore, the transcriptomic responses observed in 9 mpf  
11  
12 516 male zebrafish exposed to 14 423 ng/L of MET add to the growing body of evidence reported  
13  
14 517 in literature that MET acts as an endocrine disrupting compound<sup>15,17,18,46,53,75</sup>, by disrupting  
15  
16 518 genes and pathways associated with metabolic processes, steroidogenesis and  
17  
18 519 reproductive functions.

20 520 As indicated by the Fent (2006) and Wilkinson et al. (2022) studies<sup>11,76</sup>, average MET  
21  
22 521 concentrations in surface waters strongly increased from 2006 (100 ng/L) to 2022 (2 362.9  
23  
24 522 ng/L), with a tendency to further increases due to aging of the global population. Therefore,  
25  
26 523 these findings suggest that MET should be considered a top priority chemical to be  
27  
28 524 integrated in toxicity testing and hazard assessment strategies. In fact, MET was just  
29  
30 525 recently integrated in the proposed 4<sup>th</sup> Watch List under the Water Framework Directive  
31  
32 526 (WFD)<sup>12</sup> and in the Implementing decision (EU) 2022/1307 ([http://EUR-Lex - 32022D1307 -](http://eur-lex.europa.eu/lexuri/cs.do?uri=EN - EUR-Lex (europa.eu))  
33  
34 527 [EN - EUR-Lex \(europa.eu\)](http://eur-lex.europa.eu/lexuri/cs.do?uri=EN - EUR-Lex (europa.eu))), which reflects the urgent need to further address the risk of this  
35  
36 528 pharmaceutical to aquatic life. However, according to the proposed 4<sup>th</sup> Watch List the current  
37  
38 529 Predicted No-Effect Concentration (PNEC) for MET is 1 030 µg/L, with a proposed  
39  
40 530 environmental quality standard (EQS) of 160 µg/L<sup>12</sup> and the decision (EU) 2022/1307 settled  
41  
42 531 a maximum acceptable quantification limit for MET at 156 µg/L. Thus, it is suggested that  
43  
44 532 the current PNEC/EQS proposal for MET should be urgently reviewed, as the findings  
45  
46 533 reported here, and in other previous studies, show that MET concentrations inducing  
47  
48 534 adverse effects are several orders of magnitude lower than the proposed PNEC/EQS values  
49  
50 535 in the EU 4<sup>th</sup> Watch List of WFD.

51  
52  
53 536

54  
55 537 4. Associated content

56  
57 538 • Additional experimental methods and results (PDF).  
58  
59  
60

- 1  
2  
3  
4  
5  
6 539 • List of differentially expressed genes (DEGs) and Gene Ontology (GO) terms  
7  
8 540 involved in lipid/energy metabolism, steroid hormone biosynthesis and reproductive  
9  
10 541 processes (XLSX).  
11  
12 542

13  
14 543 5. Acknowledgments

15  
16 544 The authors would like to thank the *Biotério de Organismos Aquáticos* (BOGA) facility team,  
17  
18 545 at CIIMAR, for the help provided during the performance of the exposure bioassay.  
19

20 546

21  
22 547 6. Funding

23  
24 548 This study was developed under the projects: (1) TRANSEPIC – Exploring  
25  
26 549 Transgenerational Epigenetic Inheritance: New Methods and Strategies to Improve  
27  
28 550 Environmental Hazard and Risk Assessment of Key Contaminants of Emerging Concern  
29  
30 551 (CECs) [Reference: 2022.02922.PTDC], Financed by the Portuguese Foundation for  
31  
32 552 Science and Technology (FCT) and (2) Nor-Water – Pollutants of emerging concern in  
33  
34 553 watersheds from Galicia-northern Portugal: new tools for risk management [Reference:  
35  
36 554 0725\_NOR\_WATER\_1\_P], financed by Programa de Cooperação Interreg  
37  
38 555 Portugal/Espanha, (POCTEP) 2014–2020. The study was also supported by FCT under the  
39  
40 556 projects [UIDB/04423/2020, UIDP/04423/2020, UIDB/04033/2020 and LA/P/0126/2020]. T.  
41  
42 557 Neuparth acknowledges FCT Individual Call to Scientific Employment Stimulus 2022  
43  
44 558 (2022.02925.CEECIND). S. Barros, M. Pinheiro, H. Morais, N. Alves and M. Ribeiro,  
45  
46 559 acknowledge FCT for their Ph.D. grants PD/BD/143090/2018; SFRH/BD/147834/2019;  
47  
48 560 SFRH/BD/139762/2018, DFA/BD/6218/2020 and 2022.12763.BD, respectively. R. Montes  
49  
50 561 acknowledges Banco Santander and Universidade de Santiago de Compostela for her  
51  
52 562 outstanding researcher contract. Financial support by Xunta de Galicia (ED431C 2021/06)  
53  
54 563 and the Spanish Agencia Estatal de Investigación - MCIN/AEI/ 10.13039/501100011033  
55  
56 564 (PID2020–117686RB-C32) is also gratefully acknowledged.  
57  
58  
59  
60

565

## 566 7. References

- 567 (1) Foretz, M.; Guigas, B.; Viollet, B. Understanding the Glucoregulatory Mechanisms of  
568 Metformin in Type 2 Diabetes Mellitus. *Nat. Rev. Endocrinol.* **2019**, *15*  
569 (10), 569–589. <https://doi.org/10.1038/s41574-019-0242-2>.
- 570 (2) Krentz, A. J.; Bailey, C. J. Oral Antidiabetic Agents: Current Role in Type 2 Diabetes  
571 Mellitus. *Drugs* **2005**, *65* (3), 385–411. [https://doi.org/10.2165/00003495-200565030-  
572 00005/FIGURES/TAB8](https://doi.org/10.2165/00003495-200565030-00005/FIGURES/TAB8).
- 573 (3) Barros, S.; Ribeiro, M.; Coimbra, A. M.; Pinheiro, M.; Morais, H.; Alves, N.; Montes,  
574 R.; Rodil, R.; Quintana, J. B.; Santos, M. M.; Neuparth, T. Metformin Disrupts Danio  
575 Rerio Metabolism at Environmentally Relevant Concentrations: A Full Life-Cycle  
576 Study. *Sci. Total Environ.* **2022**, *846*, 157361.  
577 <https://doi.org/10.1016/J.SCITOTENV.2022.157361>.
- 578 (4) Adak, T.; Samadi, A.; Ünal, A. Z.; Sabuncuoğlu, S. A Reappraisal on Metformin.  
579 *Regul. Toxicol. Pharmacol.* **2018**, *92* (September 2017), 324–332.  
580 <https://doi.org/10.1016/j.yrtph.2017.12.023>.
- 581 (5) Saeedi, P.; Petersohn, I.; Salpea, P.; Malanda, B.; Karuranga, S.; Unwin, N.;  
582 Colagiuri, S.; Guariguata, L.; Motala, A. A.; Ogurtsova, K.; Shaw, J. E.; Bright, D.;  
583 Williams, R.; Saeedi, P.; Almutairi, R.; Montoya, P. A.; Basit, A.; Phane Besanç, S.;  
584 Bommer, C.; Borgnakke, W.; Boyko, E.; Chan, J.; Divakar, H.; Esteghamati, A.;  
585 Forouhi, N.; Franco, L.; Gregg, E.; Hassanein, M.; Ke, C.; Levitt, D.; Lim, L.-L.; Ogle,  
586 G. D.; Owens, D.; Pavkov, M.; Pearson-Stuttard, J.; Ramachandran, A.; Rathmann,  
587 W.; Riaz, M.; Simmons, D.; Sinclair, A.; Sobngwi, E.; Thomas, R.; Ward, H.; Wild, S.;  
588 Yang, X.; Yuen, L.; Zhang, P. Global and Regional Diabetes Prevalence Estimates  
589 for 2019 and Projections for 2030 and 2045: Results from the International Diabetes  
590 Federation Diabetes Atlas, 9th Edition. *Diabetes Res. Clin. Pract.* **2019**, *157*.

25

- 1  
2  
3  
4  
5  
6 591 <https://doi.org/10.1016/J.DIABRES.2019.107843>.
- 7  
8 592 (6) Thomas, I.; Gregg, B. Metformin; a Review of Its History and Future: From Lilac to  
9  
10 593 Longevity. *Pediatr. Diabetes* **2017**, *18* (1), 10–16.  
11  
12 594 <https://doi.org/10.1111/PEDI.12473>.
- 13  
14 595 (7) WHO. *Global Report on Diabetes*; 2016; Vol. 978.
- 15  
16 596 (8) de Solla, S. R.; Gilroy, A. M.; Klinck, J. S.; King, L. E.; McInnis, R.; Struger, J.; Backus,  
17  
18 597 S. M.; Gillis, P. L. Bioaccumulation of Pharmaceuticals and Personal Care Products  
19  
20 598 in the Unionid Mussel *Lasmigona Costata* in a River Receiving Wastewater Effluent.  
21  
22 599 *Chemosphere* **2016**, *146*, 486–496.  
23  
24 600 <https://doi.org/10.1016/J.CHEMOSPHERE.2015.12.022>.
- 25  
26 601 (9) Trautwein, C.; Berset, J. D.; Wolschke, H.; Kümmerer, K. Occurrence of the  
27  
28 602 Antidiabetic Drug Metformin and Its Ultimate Transformation Product Guanylurea in  
29  
30 603 Several Compartments of the Aquatic Cycle. *Environ. Int.* **2014**, *70*, 203–212.  
31  
32 604 <https://doi.org/10.1016/J.ENVINT.2014.05.008>.
- 33  
34 605 (10) Yao, B.; Yan, S.; Lian, L.; Yang, X.; Wan, C.; Dong, H.; Song, W. Occurrence and  
35  
36 606 Indicators of Pharmaceuticals in Chinese Streams: A Nationwide Study. *Environ.*  
37  
38 607 *Pollut.* **2018**, *236*, 889–898. <https://doi.org/10.1016/J.ENVPOL.2017.10.032>.
- 39  
40 608 (11) Wilkinson, J. L.; Boxall, A. B. A.; Kolpin, D. W.; Leung, K. M. Y.; Lai, R. W. S.; Galban-  
41  
42 609 Malag, C.; Adell, A. D.; Mondon, J.; Metian, M.; Marchant, R. A.; Bouzas-Monroy, A.;  
43  
44 610 Cuni-Sanchez, A.; Coors, A.; Carriquiriborde, P.; Rojo, M.; Gordon, C.; Cara, M.;  
45  
46 611 Moermond, M.; Luarte, T.; Petrosyan, V.; Perikhanyan, Y.; Mahon, C. S.; McGurk, C.  
47  
48 612 J.; Hofmann, T.; Kormoker, T.; Iniguez, V.; Guzman-Otazo, J.; Tavares, J. L.; de  
49  
50 613 Figueiredo, F. G.; Razzolini, M. T. P.; Dougnon, V.; Gbaguidi, G.; Traore, O.; Blais, J.  
51  
52 614 M.; Kimpe, L. E.; Wong, M.; Wong, D.; Ntchantcho, R.; Pizarro, J.; Ying, G. G.; Chen,  
53  
54 615 C. E.; Paez, M.; Martinez-Lara, J.; Otamonga, J. P.; Pote, J.; Ifo, S. A.; Wilson, P.;  
55  
56 616 Echeverria-Saenz, S.; Udikovic-Kolic, N.; Milakovic, M.; Fatta-Kassinos, D.; Ioannou-

- 1  
2  
3  
4  
5  
6 617 Ttofa, L.; Belusova, V.; Vymazal, J.; Cardenas-Bustamante, M.; Kassa, B. A.; Garric,  
7  
8 618 J.; Chaumot, A.; Gibba, P.; Kunchulia, I.; Seidensticker, S.; Lyberatos, G.;  
9  
10 619 Halldorsson, H. P.; Melling, M.; Shashidhar, T.; Lamba, M.; Nastiti, A.; Supriatin, A.;  
11  
12 620 Pourang, N.; Abedini, A.; Abdullah, O.; Gharbia, S. S.; Pilla, F.; Chefetz, B.; Topaz,  
13  
14 621 T.; Yao, K. M.; Aubakirova, B.; Beisenova, R.; Olaka, L.; Mulu, J. K.; Chatanga, P.;  
15  
16 622 Ntuli, V.; Blama, N. T.; Sherif, S.; Aris, A. Z.; Looi, L. J.; Niang, M.; Traore, S. T.;  
17  
18 623 Oldenkamp, R.; Ogunbanwo, O.; Ashfaq, M.; Iqbal, M.; Abdeen, Z.; O'Dea, A.;  
19  
20 624 Morales-Saldaña, J. M.; Custodio, M.; de la Cruz, H.; Navarrete, I.; Carvalho, F.;  
21  
22 625 Gogra, A. B.; Koroma, B. M.; Cerkvenik-Flajs, V.; Gombac, M.; Thwala, M.; Choi, K.;  
23  
24 626 Kang, H.; Celestino Ladu, J. L.; Rico, A.; Amerasinghe, P.; Sobek, A.; Horlitz, G.;  
25  
26 627 Zenker, A. K.; King, A. C.; Jiang, J. J.; Kariuki, R.; Tumbo, M.; Tezel, U.; Onay, T. T.;  
27  
28 628 Lejju, J. B.; Vystavna, Y.; Vergeles, Y.; Heinzen, H.; Perez-Parada, A.; Sims, D. B.;  
29  
30 629 Figy, M.; Good, D.; Teta, C. Pharmaceutical Pollution of the World's Rivers. *Proc.*  
31  
32 630 *Natl. Acad. Sci. U. S. A.* **2022**, *119* (8), e2113947119.  
33  
34 631 [https://doi.org/10.1073/PNAS.2113947119/SUPPL\\_FILE/PNAS.2113947119.SD12](https://doi.org/10.1073/PNAS.2113947119/SUPPL_FILE/PNAS.2113947119.SD12).  
35  
36 632 XLSX.  
37  
38  
39 633 (12) Gomez Cortes, L.; Marinov, D.; Sanseverino, I.; Navarro Cuenca, A.; Niegowska, M.;  
40  
41 634 Porcel Rodriguez, E.; Stefanelli, F.; Lettieri, T.; European Commission. Joint  
42  
43 635 Research Centre. Selection of Substances for the 4th Watch List under the Water  
44  
45 636 Framework Directive. **2022**. <https://doi.org/10.2760/01939>.  
46  
47 637 (13) García-García, G.; Reyes-Carrillo, G. I.; Sarma, S. S. S.; Nandini, S. Population Level  
48  
49 638 Responses of Rotifers (*Brachionus Calyciflorus* and *Plationus Patulus*) to the Anti-  
50  
51 639 Diabetic Drug, Metformin. *J. Environ. Biol.* **2017**, *38* (6 Special issue), 1213–1219.  
52  
53 640 [https://doi.org/10.22438/JEB/38/6\(SI\)/06](https://doi.org/10.22438/JEB/38/6(SI)/06).  
54  
55 641 (14) Godoy, A. A.; Domingues, I.; Arsénia Nogueira, A. J.; Kummrow, F. Ecotoxicological  
56  
57 642 Effects, Water Quality Standards and Risk Assessment for the Anti-Diabetic  
58  
59  
60

- 1  
2  
3  
4  
5  
6 643 Metformin. *Environ. Pollut.* **2018**, *243*, 534–542.  
7  
8 644 <https://doi.org/10.1016/j.envpol.2018.09.031>.  
9  
10 645 (15) Niemuth, N. J.; Klaper, R. D. Emerging Wastewater Contaminant Metformin Causes  
11 Intersex and Reduced Fecundity in Fish. *Chemosphere* **2015**, *135*, 38–45.  
12 646  
13 647 <https://doi.org/10.1016/j.chemosphere.2015.03.060>.  
14  
15  
16 648 (16) Jacob, S.; Dötsch, A.; Knoll, S.; Köhler, H. R.; Rogall, E.; Stoll, D.; Tisler, S.; Huhn,  
17 C.; Schwartz, T.; Zwiener, C.; Triebkorn, R. Does the Antidiabetic Drug Metformin  
18 649 Affect Embryo Development and the Health of Brown Trout (*Salmo Trutta f. Fario*)?  
19 *Environ. Sci. Eur.* **2018**, *30* (1). <https://doi.org/10.1186/s12302-018-0179-4>.  
20 650  
21  
22 651  
23  
24 652 (17) Lee, J. W.; Shin, Y. J.; Kim, H.; Kim, H.; Kim, J.; Min, S. A.; Kim, P.; Yu, S. Do; Park,  
25 K. Metformin-Induced Endocrine Disruption and Oxidative Stress of *Oryzias Latipes*  
26 653 on Two-Generational Condition. *J. Hazard. Mater.* **2019**, *367*, 171–181.  
27 654  
28 655 <https://doi.org/10.1016/J.JHAZMAT.2018.12.084>.  
29  
30  
31  
32 656 (18) Ussery, E.; Bridges, K. N.; Pandelides, Z.; Kirkwood, A. E.; Bonetta, D.; Venables, B.  
33 657 J.; Guchardi, J.; Holdway, D. Effects of Environmentally Relevant Metformin  
34 658 Exposure on Japanese Medaka (*Oryzias Latipes*). *Aquat. Toxicol.* **2018**, *205* (July),  
35 659 58–65. <https://doi.org/10.1016/j.aquatox.2018.10.003>.  
36  
37  
38  
39  
40 660 (19) Wei, J.; Qi, H.; Liu, K.; Zhao, C.; Bian, Y.; Li, G. Effects of Metformin on Life Span,  
41 661 Cognitive Ability, and Inflammatory Response in a Short-Lived Fish. *Journals*  
42 662 *Gerontol. Ser. A* **2020**, *75* (11), 2042–2050.  
43 663 <https://doi.org/10.1093/GERONA/GLAA109>.  
44  
45  
46  
47  
48 664 (20) Soares, J.; Coimbra, A. M.; Reis-Henriques, M. A.; Monteiro, N. M.; Vieira, M. N.;  
49 665 Oliveira, J. M. A.; Guedes-Dias, P.; Fontáinhas-Fernandes, A.; Parra, S. S.; Carvalho,  
50 666 A. P.; Castro, L. F. C.; Santos, M. M. Disruption of Zebrafish (*Danio Rerio*) Embryonic  
51 667 Development after Full Life-Cycle Parental Exposure to Low Levels of  
52 668 Ethinylestradiol. *Aquat. Toxicol.* **2009**, *95* (4), 330–338.

- 1  
2  
3  
4  
5  
6 669 <https://doi.org/10.1016/J.AQUATOX.2009.07.021>.
- 7  
8 670 (21) OECD. Test No. 236: Fish Embryo Acute Toxicity (FET) Test. *OECD Guidel. Test.*  
9  
10 671 *Chem. Sect. 2, OECD Publ. 2013, No. July, 1–22.*  
11  
12 672 <https://doi.org/10.1787/9789264203709-en>.
- 13  
14 673 (22) Coimbra, A. M.; Peixoto, M. J.; Coelho, I.; Lacerda, R.; Carvalho, A. P.; Gesto, M.;  
15  
16 674 Lyssimachou, A.; Lima, D.; Soares, J.; André, A.; Capitão, A.; Castro, L. F. C.; Santos,  
17  
18 675 M. M. Chronic Effects of Clofibrac Acid in Zebrafish (*Danio Rerio*): A Multigenerational  
19  
20 676 Study. *Aquat. Toxicol.* **2015**, *160*, 76–86.  
21  
22 677 <https://doi.org/10.1016/j.aquatox.2015.01.013>.
- 23  
24 678 (23) Phillips, J.; Akemann, C.; Shields, J. N.; Wu, C. C.; Meyer, D. N.; Baker, B. B.; Pitts,  
25  
26 679 D. K.; Baker, T. R. Developmental Phenotypic and Transcriptomic Effects of Exposure  
27  
28 680 to Nanomolar Levels of Metformin in Zebrafish. *Environ. Toxicol. Pharmacol.* **2021**,  
29  
30 681 *87* (July), 103716. <https://doi.org/10.1016/j.etap.2021.103716>.
- 31  
32 682 (24) Elizalde-Velázquez, G. A.; Gómez-Oliván, L. M.; García-Medina, S.; Islas-Flores, H.;  
33  
34 683 Hernández-Navarro, M. D.; Galar-Martínez, M. Antidiabetic Drug Metformin Disrupts  
35  
36 684 the Embryogenesis in Zebrafish through an Oxidative Stress Mechanism.  
37  
38 685 *Chemosphere* **2021**, *285* (May).  
39  
40 686 <https://doi.org/10.1016/j.chemosphere.2021.131213>.
- 41  
42 687 (25) Parrott, J. L.; Pacepavicius, G.; Shires, K.; Clarence, S.; Khan, H.; Gardiner, M.;  
43  
44 688 Sullivan, C.; Alae, M. Fathead Minnow Exposed to Environmentally Relevant  
45  
46 689 Concentrations of Metformin for One Life Cycle Show No Adverse Effects. *Facets*  
47  
48 690 **2021**, *6*, 998–1023. <https://doi.org/10.1139/facets-2020-0106>.
- 49  
50 691 (26) Parrott, J. L.; Restivo, V. E.; Kidd, K. A.; Zhu, J.; Shires, K.; Clarence, S.; Khan, H.;  
51  
52 692 Sullivan, C.; Pacepavicius, G.; Alae, M. Chronic Embryo-Larval Exposure of  
53  
54 693 Fathead Minnows to the Pharmaceutical Drug Metformin: Survival, Growth, and  
55  
56 694 Microbiome Responses. *Environ. Toxicol. Chem.* **2021**, *00* (00), 1–13.

- 1  
2  
3  
4  
5  
6 695 <https://doi.org/10.1002/etc.5054>.
- 7  
8 696 (27) Nielsen, K. M.; Decamp, L.; Birgisson, M.; Palace, V. P.; Kidd, K. A.; Parrott, J. L.;  
9  
10 697 McMaster, M. E.; Alaei, M.; Blandford, N.; Ussery, E. J. Comparative Effects of  
11  
12 698 Embryonic Metformin Exposure on Wild and Laboratory-Spawned Fathead Minnow  
13  
14 699 (Pimephales Promelas) Populations. *Environ. Sci. Technol.* **2022**, *56* (14), 10193–  
15  
16 700 10203.  
17  
18 701 [https://doi.org/10.1021/ACS.EST.2C01079/SUPPL\\_FILE/ES2C01079\\_SI\\_001.PDF](https://doi.org/10.1021/ACS.EST.2C01079/SUPPL_FILE/ES2C01079_SI_001.PDF).
- 19  
20 702 (28) Neuparth, T.; Martins, C.; Carmen, B.; Costa, M. Hypocholesterolaemic  
21  
22 703 Pharmaceutical Simvastatin Disrupts Reproduction and Population Growth of the  
23  
24 704 Amphipod *Gammarus Locusta* at the Ng/L Range. *Aquat. Toxicol.* **2014**.
- 25  
26 705 (29) Neuparth, T.; Machado, A. M.; Montes, R.; Rodil, R.; Barros, S.; Alves, N.; Ruivo, R.;  
27  
28 706 Castro, L. F. C.; Quintana, J. B.; Santos, M. M. Transgenerational Inheritance of  
29  
30 707 Chemical-Induced Signature: A Case Study with Simvastatin. *Environ. Int.* **2020**, *144*,  
31  
32 708 106020. <https://doi.org/10.1016/J.ENVINT.2020.106020>.
- 33  
34 709 (30) Neuparth, T.; Alves, N.; Machado, A. M.; Pinheiro, M.; Montes, R.; Rodil, R.; Barros,  
35  
36 710 S.; Ruivo, R.; Castro, L. F. C.; Quintana, J. B.; Santos, M. M. Neuroendocrine  
37  
38 711 Pathways at Risk? Simvastatin Induces Inter and Transgenerational Disruption in the  
39  
40 712 Keystone Amphipod *Gammarus Locusta*. *Aquat. Toxicol.* **2022**, *244*, 106095.  
41  
42 713 <https://doi.org/10.1016/J.AQUATOX.2022.106095>.
- 43  
44 714 (31) Calabrese, E. J. Hormesis: A Revolution in Toxicology, Risk Assessment and  
45  
46 715 Medicine. *EMBO Rep.* **2004**, *5 Spec No* (1S), S37-40.  
47  
48 716 <https://doi.org/10.1038/sj.embor.7400222>.
- 49  
50 717 (32) Neuparth, T.; Correia, A. D.; Costa, F. O.; Lima, G.; Costa, M. H. Multi-Level  
51  
52 718 Assessment of Chronic Toxicity of Estuarine Sediments with the Amphipod  
53  
54 719 *Gammarus Locusta*: I. Biochemical Endpoints. *Mar. Environ. Res.* **2005**, *60* (1), 69–  
55  
56 720 91. <https://doi.org/10.1016/J.MARENRES.2004.08.006>.

- 1  
2  
3  
4  
5  
6 721 (33) Agathokleous, E.; Calabrese, E. J. Hormesis: The Dose Response for the 21st  
7  
8 722 Century: The Future Has Arrived. *Toxicology* **2019**, *425*, 152249.  
9  
10 723 <https://doi.org/10.1016/J.TOX.2019.152249>.  
11  
12 724 (34) Calabrese, E. J. Hormesis: Why It Is Important to Toxicology and Toxicologists.  
13  
14 725 *Environ. Toxicol. Chem.* **2008**, *27* (7), 1451–1474. <https://doi.org/10.1897/07-541.1>.  
15  
16 726 (35) Banerjee, P.; Surendran, H.; Chowdhury, D. R.; Prabhakar, K.; Pal, R. Metformin  
17  
18 727 Mediated Reversal of Epithelial to Mesenchymal Transition Is Triggered by Epigenetic  
19  
20 728 Changes in E-Cadherin Promoter. *J. Mol. Med.* **2016**, *94* (12), 1397–1409.  
21  
22 729 <https://doi.org/10.1007/S00109-016-1455-7/FIGURES/7>.  
23  
24 730 (36) Schointuch, M. N.; Gilliam, T. P.; Stine, J. E.; Han, X.; Zhou, C.; Gehrig, P. A.; Kim,  
25  
26 731 K.; Bae-Jump, V. L. Simvastatin, an HMG-CoA Reductase Inhibitor, Exhibits Anti-  
27  
28 732 Metastatic and Anti-Tumorigenic Effects in Endometrial Cancer. *Gynecol. Oncol.*  
29  
30 733 **2014**, *134* (2), 346–355. <https://doi.org/10.1016/j.ygyno.2014.05.015>.  
31  
32 734 (37) Zhong, T.; Men, Y.; Lu, L.; Geng, T.; Zhou, J.; Mitsuhashi, A.; Shozu, M.; Maihle, N.  
33  
34 735 J.; Carmichael, G. G.; Taylor, H. S.; Huang, Y. Metformin Alters DNA Methylation  
35  
36 736 Genome-Wide via the H19/SAHH Axis. *Oncogene* **2016**, *36* (17), 2345–  
37  
38 737 2354. <https://doi.org/10.1038/onc.2016.391>.  
39  
40 738 (38) Marin, T. L.; Gongol, B.; Zhang, F.; Martin, M.; Johnson, D. A.; Xiao, H.; Wang, Y.;  
41  
42 739 Subramaniam, S.; Chien, S.; Shyy, J. Y. J. AMPK Promotes Mitochondrial Biogenesis  
43  
44 740 and Function by Phosphorylating the Epigenetic Factors DNMT1, RBBP7, and HAT1.  
45  
46 741 *Sci. Signal.* **2017**, *10* (464).  
47  
48 742 [https://doi.org/10.1126/SCISIGNAL.AAF7478/SUPPL\\_FILE/AAF7478\\_SM.PDF](https://doi.org/10.1126/SCISIGNAL.AAF7478/SUPPL_FILE/AAF7478_SM.PDF).  
49  
50 743 (39) Khan, S.; Jena, G. Sodium Butyrate Reduces Insulin-Resistance, Fat Accumulation  
51  
52 744 and Dyslipidemia in Type-2 Diabetic Rat: A Comparative Study with Metformin.  
53  
54 745 *Chem. Biol. Interact.* **2016**, *254*, 124–134. <https://doi.org/10.1016/J.CBI.2016.06.007>.  
55  
56 746 (40) Blandino, G.; Valerio, M.; Cioce, M.; Mori, F.; Casadei, L.; Pulito, C.; Sacconi, A.;  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6 747 Biagioni, F.; Cortese, G.; Galanti, S.; Manetti, C.; Citro, G.; Muti, P.; Strano, S.  
7  
8 748 Metformin Elicits Anticancer Effects through the Sequential Modulation of DICER and  
9  
10 749 C-MYC. *Nat. Commun.* **2012**, *31*, **2012**, *3* (1), 1–11.  
11  
12 750 <https://doi.org/10.1038/ncomms1859>.  
13  
14 751 (41) Cabello, P.; Pineda, B.; Tormo, E.; Lluch, A.; Eroles, P. The Antitumor Effect of  
15  
16 752 Metformin Is Mediated by MiR-26a in Breast Cancer. *Int. J. Mol. Sci.* **2016**, *Vol. 17*,  
17  
18 753 *Page 1298* **2016**, *17* (8), 1298. <https://doi.org/10.3390/IJMS17081298>.  
19  
20 754 (42) Oliveras-Ferraros, C.; Cufí, S.; Vazquez-Martin, A.; Torres-Garcia, V. Z.; Barco, S.  
21  
22 755 Del; Martin-Castillo, B.; Menendez, J. A. Micro(Mi)RNA Expression Profile of Breast  
23  
24 756 Cancer Epithelial Cells Treated with the Anti-Diabetic Drug Metformin: Induction of  
25  
26 757 the Tumor Suppressor MiRNA Let-7a and Suppression of the TGF $\beta$ -Induced  
27  
28 758 OncomiR MiRNA-181a. <http://dx.doi.org/10.4161/cc.10.7.15210> **2011**, *10* (7), 1144–  
29  
30 759 1151. <https://doi.org/10.4161/CC.10.7.15210>.  
31  
32 760 (43) Lee, K. W.; Webb, S. E.; Miller, A. L. A Wave of Free Cytosolic Calcium Traverses  
33  
34 761 Zebrafish Eggs on Activation. *Dev. Biol.* **1999**, *214* (1), 168–180.  
35  
36 762 <https://doi.org/10.1006/DBIO.1999.9396>.  
37  
38 763 (44) Mei, W.; Lee, K. W.; Marlow, F. L.; Miller, A. L.; Mullins, M. C. HnRNP I Is Required  
39  
40 764 to Generate the Ca<sup>2+</sup> Signal That Causes Egg Activation in Zebrafish. *Development*  
41  
42 765 **2009**, *136* (17), 3007. <https://doi.org/10.1242/DEV.037879>.  
43  
44 766 (45) Blackwell, B. R.; Ankley, G. T.; Biales, A. D.; Cavallin, J. E.; Cole, A. R.; Collette, T.  
45  
46 767 W.; Ekman, D. R.; Hofer, R. N.; Huang, W.; Jensen, K. M.; Kahl, M. D.; Kittelson, A.  
47  
48 768 R.; Romano, S. N.; See, M. J.; Teng, Q.; Tilton, C. B.; Villeneuve, D. L. Effects of  
49  
50 769 Metformin and Its Metabolite Guanylurea on Fathead Minnow (*Pimephales Promelas*)  
51  
52 770 Reproduction. *Environ. Toxicol. Chem.* **2022**, *41* (11), 2708–2720.  
53  
54 771 <https://doi.org/10.1002/ETC.5450>.  
55  
56 772 (46) Niemuth, N. J.; Jordan, R.; Crago, J.; Blanksma, C.; Johnson, R.; Klaper, R. D.

- 1  
2  
3  
4  
5  
6 773 Metformin Exposure at Environmentally Relevant Concentrations Causes Potential  
7  
8 774 Endocrine Disruption in Adult Male Fish. *Environ. Toxicol. Chem.* **2015**, *34* (2), 291–  
9  
10 775 296. <https://doi.org/10.1002/ETC.2793>.  
11  
12 776 (47) van den Hurk, R.; Schoonen, W. G. E. J.; van Zoelen, G. A.; Lambert, J. G. D. The  
13  
14 777 Biosynthesis of Steroid Glucuronides in the Testis of the Zebrafish, *Brachydanio*  
15  
16 778 *Rerio*, and Their Pheromonal Function as Ovulation Inducers. *Gen. Comp.*  
17  
18 779 *Endocrinol.* **1987**, *68* (2), 179–188. [https://doi.org/10.1016/0016-6480\(87\)90027-X](https://doi.org/10.1016/0016-6480(87)90027-X).  
19  
20 780 (48) Gerlach, G. Pheromonal Regulation of Reproductive Success in Female Zebrafish:  
21  
22 781 Female Suppression and Male Enhancement. *Anim. Behav.* **2006**, *72* (5), 1119–  
23  
24 782 1124. <https://doi.org/10.1016/J.ANBEHAV.2006.03.009>.  
25  
26 783 (49) Tokarz, J.; Möller, G.; Hrabě De Angelis, M.; Adamski, J. Zebrafish and Steroids:  
27  
28 784 What Do We Know and What Do We Need to Know? *J. Steroid Biochem. Mol. Biol.*  
29  
30 785 **2013**, *137*, 165–173. <https://doi.org/10.1016/J.JSBMB.2013.01.003>.  
31  
32 786 (50) Tokarz, J.; Möller, G.; Hrabě De Angelis, M.; Adamski, J. Steroids in Teleost Fishes:  
33  
34 787 A Functional Point of View. *Steroids* **2015**, *103*, 123–144.  
35  
36 788 <https://doi.org/10.1016/J.STEROIDS.2015.06.011>.  
37  
38 789 (51) Hirsch, A.; Hahn, D.; Kempná, P.; Hofer, G.; Nuoffer, J. M.; Mullis, P. E.; Flück, C. E.  
39  
40 790 Metformin Inhibits Human Androgen Production by Regulating Steroidogenic  
41  
42 791 Enzymes HSD3B2 and CYP17A1 and Complex I Activity of the Respiratory Chain.  
43  
44 792 *Endocrinology* **2012**, *153* (9), 4354–4366. <https://doi.org/10.1210/en.2012-1145>.  
45  
46 793 (52) Shurrab, N. T.; Arafa, E. S. A. Metformin: A Review of Its Therapeutic Efficacy and  
47  
48 794 Adverse Effects. *Obes. Med.* **2020**, *17*, 100186.  
49  
50 795 <https://doi.org/10.1016/J.OBMED.2020.100186>.  
51  
52 796 (53) Crago, J.; Bui, C.; Grewal, S.; Schlenk, D. Age-Dependent Effects in Fathead  
53  
54 797 Minnows from the Anti-Diabetic Drug Metformin. *Gen. Comp. Endocrinol.* **2016**, *232*,  
55  
56 798 185–190. <https://doi.org/10.1016/J.YGCEN.2015.12.030>.  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6 799 (54) Levi, L.; Pekarski, I.; Gutman, E.; Fortina, P.; Hyslop, T.; Biran, J.; Levavi-Sivan, B.;  
7  
8 800 Lubzens, E. Revealing Genes Associated with Vitellogenesis in the Liver of the  
9  
10 801 Zebrafish (*Danio Rerio*) by Transcriptome Profiling. *BMC Genomics* **2009**, *10* (1), 1–  
11  
12 802 17. <https://doi.org/10.1186/1471-2164-10-141/FIGURES/10>.  
13  
14 803 (55) Levi, L.; Ziv, T.; Admon, A.; Levavi-Sivan, B.; Lubzens, E. Insight into Molecular  
15  
16 804 Pathways of Retinal Metabolism, Associated with Vitellogenesis in Zebrafish. *Am. J.*  
17  
18 805 *Physiol. Endocrinol. Metab.* **2012**, *302* (6), 626–644.  
19  
20 806 <https://doi.org/10.1152/AJPENDO.00310.2011>.  
21  
22 807 (56) Islinger, M.; Yuan, H.; Voelkl, A.; Braunbeck, T. Measurement of Vitellogenin Gene  
23  
24 808 Expression by RT-PCR as a Tool to Identify Endocrine Disruption in Japanese  
25  
26 809 Medaka (*Oryzias Latipes*). <http://dx.doi.org/10.1080/13547500110086919> **2008**, *7*  
27  
28 810 (1), 80–93. <https://doi.org/10.1080/13547500110086919>.  
29  
30 811 (57) Muncke, J.; Eggen, R. I. L. Vitellogenin 1 mRNA as an Early Molecular Biomarker for  
31  
32 812 Endocrine Disruption in Developing Zebrafish (*Danio Rerio*). *Environ. Toxicol. Chem.*  
33  
34 813 **2006**, *25* (10), 2734–2741. <https://doi.org/10.1897/05-683R.1>.  
35  
36 814 (58) Crago, J.; Bui, C.; Grewal, S.; Schlenk, D. Age-Dependent Effects in Fathead  
37  
38 815 Minnows from the Anti-Diabetic Drug Metformin. *Gen. Comp. Endocrinol.* **2016**, *232*,  
39  
40 816 185–190. <https://doi.org/10.1016/j.ygcen.2015.12.030>.  
41  
42 817 (59) Ambrosio-Albuquerque, E. P.; Cusioli, L. F.; Bergamasco, R.; Sinópolis Gigliolli, A.  
43  
44 818 A.; Lupepsa, L.; Paupitz, B. R.; Barbieri, P. A.; Borin-Carvalho, L. A.; de Brito Portela-  
45  
46 819 Castro, A. L. Metformin Environmental Exposure: A Systematic Review. *Environ.*  
47  
48 820 *Toxicol. Pharmacol.* **2021**, *83* (September 2020).  
49  
50 821 <https://doi.org/10.1016/j.etap.2021.103588>.  
51  
52 822 (60) Blair, B. D.; Crago, J. P.; Hedman, C. J.; Klaper, R. D. Pharmaceuticals and Personal  
53  
54 823 Care Products Found in the Great Lakes above Concentrations of Environmental  
55  
56 824 Concern. *Chemosphere* **2013**, *93* (9), 2116–2123.

- 1  
2  
3  
4  
5  
6 825 <https://doi.org/10.1016/J.CHEMOSPHERE.2013.07.057>.
- 7  
8 826 (61) Elliott, S. M.; Brigham, M. E.; Lee, K. E.; Banda, J. A.; Choy, S. J.; Gefell, D. J.;  
9  
10 827 Minarik, T. A.; Moore, J. N.; Jorgenson, Z. G. Contaminants of Emerging Concern in  
11  
12 828 Tributaries to the Laurentian Great Lakes: I. Patterns of Occurrence. *PLoS One* **2017**,  
13  
14 829 *12* (9), e0182868. <https://doi.org/10.1371/JOURNAL.PONE.0182868>.
- 15  
16 830 (62) Johnson, A. C.; Dumont, E.; Williams, R. J.; Oldenkamp, R.; Cisowska, I.; Sumpter,  
17  
18 831 J. P. Do Concentrations of Ethinylestradiol, Estradiol, and Diclofenac in European  
19  
20 832 Rivers Exceed Proposed EU Environmental Quality Standards? *Environ. Sci.*  
21  
22 833 *Technol.* **2013**, *47* (21), 12297–12304.  
23  
24 834 [https://doi.org/10.1021/ES4030035/SUPPL\\_FILE/ES4030035\\_SI\\_001.PDF](https://doi.org/10.1021/ES4030035/SUPPL_FILE/ES4030035_SI_001.PDF).
- 25  
26 835 (63) Ojogoro, J. O.; Scrimshaw, M. D.; Sumpter, J. P. Steroid Hormones in the Aquatic  
27  
28 836 Environment. *Sci. Total Environ.* **2021**, *792*, 148306.  
29  
30 837 <https://doi.org/10.1016/J.SCITOTENV.2021.148306>.
- 31  
32 838 (64) Thorpe, K. L.; Maack, G.; Benstead, R.; Tyler, C. R. Estrogenic Wastewater  
33  
34 839 Treatment Works Effluents Reduce Egg Production in Fish. *Environ. Sci. Technol.*  
35  
36 840 **2009**, *43* (8), 2976–2982. <https://doi.org/10.1021/ES803103C>.
- 37  
38 841 (65) MacLaren, R. D.; Wisniewski, K.; MacLaren, C. Environmental Concentrations of  
39  
40 842 Metformin Exposure Affect Aggressive Behavior in the Siamese Fighting Fish, *Betta*  
41  
42 843 *Splendens*. *PLoS One* **2018**, *13* (5), e0197259.  
43  
44 844 <https://doi.org/10.1371/JOURNAL.PONE.0197259>.
- 45  
46 845 (66) Han, X.; Alam, M. N.; Cao, M.; Wang, X.; Cen, M.; Tian, M.; Lu, Y.; Huang, Q. Low  
47  
48 846 Levels of Perfluorooctanoic Acid Exposure Activates Steroid Hormone Biosynthesis  
49  
50 847 through Repressing Histone Methylation in Rats. *Environ. Sci. Technol.* **2022**, *56* (9),  
51  
52 848 5664–5672.  
53  
54 849 [https://doi.org/10.1021/ACS.EST.1C08885/SUPPL\\_FILE/ES1C08885\\_SI\\_001.PDF](https://doi.org/10.1021/ACS.EST.1C08885/SUPPL_FILE/ES1C08885_SI_001.PDF).
- 55  
56 850 (67) Rone, M. B.; Fan, J.; Papadopoulos, V. Cholesterol Transport in Steroid Biosynthesis:

- 1  
2  
3  
4  
5  
6 851 Role of Protein-Protein Interactions and Implications in Disease States. *Biochim.*  
7  
8 852 *Biophys. Acta* **2009**, *1791* (7), 646. <https://doi.org/10.1016/J.BBALIP.2009.03.001>.  
9  
10 853 (68) Hsu, H. J.; Hsu, N. C.; Hu, M. C.; Chung, B. C. Steroidogenesis in Zebrafish and  
11  
12 854 Mouse Models. *Mol. Cell. Endocrinol.* **2006**, *248* (1–2), 160–163.  
13  
14 855 <https://doi.org/10.1016/J.MCE.2005.10.011>.  
15  
16 856 (69) Li, M.; Wang, L.; Wang, H.; Liang, H.; Zheng, Y.; Qin, F.; Liu, S.; Zhang, Y.; Wang, Z.  
17  
18 857 Molecular Cloning and Characterization of Amh, Dax1 and Cyp19a1a Genes and  
19  
20 858 Their Response to 17 $\alpha$ -Methyltestosterone in Pengze Crucian Carp. *Comp. Biochem.*  
21  
22 859 *Physiol. Part C Toxicol. Pharmacol.* **2013**, *157* (4), 372–381.  
23  
24 860 <https://doi.org/10.1016/J.CBPC.2013.03.005>.  
25  
26 861 (70) Zhang, Z.; Liu, W.; Qu, Y.; Quan, X.; Zeng, P.; He, M.; Zhou, Y.; Liu, R. Transcriptomic  
27  
28 862 Profiles in Zebrafish Liver Permit the Discrimination of Surface Water with Pollution  
29  
30 863 Gradient and Different Discharges. *Int. J. Environ. Res. Public Heal.* *2018*, *Vol. 15*,  
31  
32 864 *Page 1648* **2018**, *15* (8), 1648. <https://doi.org/10.3390/IJERPH15081648>.  
33  
34 865 (71) Goldstone, J. V.; McArthur, A. G.; Kubota, A.; Zanette, J.; Parente, T.; Jönsson, M.  
35  
36 866 E.; Nelson, D. R.; Stegeman, J. J. Identification and Developmental Expression of the  
37  
38 867 Full Complement of Cytochrome P450 Genes in Zebrafish. *BMC Genomics* *2010* *111*  
39  
40 868 **2010**, *11* (1), 1–21. <https://doi.org/10.1186/1471-2164-11-643>.  
41  
42 869 (72) Gao, S.; Zhang, T.; Zhou, X.; Zhao, Y.; Li, Q.; Guo, Y.; Cheng, H.; Zhou, R. Molecular  
43  
44 870 Cloning, Expression of Sox5 and Its down-Regulation of Dmrt1 Transcription in  
45  
46 871 Zebrafish. *J. Exp. Zool. Part B Mol. Dev. Evol.* **2005**, *304B* (5), 476–483.  
47  
48 872 <https://doi.org/10.1002/JEZ.B.21053>.  
49  
50 873 (73) So, J.; Ningappa, M.; Glessner, J.; Min, J.; Ashokkumar, C.; Ranganathan, S.; Higgs,  
51  
52 874 B. W.; Li, D.; Sun, Q.; Schmitt, L.; Biery, A. C.; Dobrowolski, S.; Trautz, C.; Fuhrman,  
53  
54 875 L.; Schwartz, M. C.; Klena, N. T.; Fusco, J.; Prasad, K.; Adenuga, M.; Mohamed,  
55  
56 876 N.; Yan, Q.; Chen, W.; Horne, W.; Dhawan, A.; Sharif, K.; Kelly, D.; Squires, R. H.;

- 1  
2  
3  
4  
5  
6 877 Gittes, G. K.; Hakonarson, H.; Morell, V.; Lo, C.; Subramaniam, S.; Shin, D.; Sindhi,  
7  
8 878 R. Biliary-Atresia-Associated Mannosidase-1-Alpha-2 Gene Regulates Biliary and  
9  
10 879 Ciliary Morphogenesis and Laterality. *Front. Physiol.* **2020**, *11*.  
11  
12 880 <https://doi.org/10.3389/FPHYS.2020.538701/FULL>.  
13  
14 881 (74) Caldwell, D. J.; D'Aco, V.; Davidson, T.; Kappler, K.; Murray-Smith, R. J.; Owen, S.  
15  
16 882 F.; Robinson, P. F.; Simon-Hettich, B.; Straub, J. O.; Tell, J. Environmental Risk  
17  
18 883 Assessment of Metformin and Its Transformation Product Guanylurea: II. Occurrence  
19  
20 884 in Surface Waters of Europe and the United States and Derivation of Predicted No-  
21  
22 885 Effect Concentrations. *Chemosphere* **2019**, *216*, 855–865.  
23  
24 886 <https://doi.org/10.1016/J.CHEMOSPHERE.2018.10.038>.  
25  
26 887 (75) Niemuth, N. J.; Klaper, R. D. Low-Dose Metformin Exposure Causes Changes in  
27  
28 888 Expression of Endocrine Disruption-Associated Genes. *Aquat. Toxicol.* **2018**, *195*  
29  
30 889 (December 2017), 33–40. <https://doi.org/10.1016/j.aquatox.2017.12.003>.  
31  
32 890 (76) Fent, K.; Weston, A. A.; Caminada, D. Ecotoxicology of Human Pharmaceuticals.  
33  
34 891 *Aquat. Toxicol.* **2006**, *76* (2), 122–159.  
35  
36 892 <https://doi.org/10.1016/j.aquatox.2005.09.009>.  
37  
38  
39 893

## Supporting information

### **Are fish populations at risk? Metformin disrupts zebrafish development and reproductive processes at chronic environmentally relevant concentrations**

Susana Barros <sup>a,b</sup>, Néelson Alves <sup>a,c</sup>, Marlene Pinheiro <sup>a,c</sup>, Marta Ribeiro <sup>a,c</sup>, Hugo Morais <sup>a,c</sup>, Rosa Montes <sup>d</sup>, Rosario Rodil <sup>d</sup>, José Benito Quintana <sup>d</sup>, Ana M. Coimbra <sup>b,e</sup>, Miguel. M. Santos <sup>a,c,\*</sup>, Teresa Neuparth <sup>a,\*,#</sup>

# Correspondence to: T. Neuparth, CIIMAR—Interdisciplinary Centre of Marine and Environmental Research, Endocrine Disruptors and Emerging Contaminants Group, University of Porto, Avenida General Norton de Matos, S/N, 4450-208 Matosinhos, Portugal

\* Corresponding author(s): [tneuparth@ciimar.up.pt](mailto:tneuparth@ciimar.up.pt) (T. Neuparth); [miguel.santos@fc.up.pt](mailto:miguel.santos@fc.up.pt) (M. M. Santos)

<sup>a</sup> CIIMAR—Interdisciplinary Centre of Marine and Environmental Research, Endocrine Disruptors and Emerging Contaminants Group, University of Porto, Avenida General Norton de Matos, S/N, 4450-208 Matosinhos, Portugal

<sup>b</sup> CITAB - Centre for the Research and Technology of Agro-Environmental and Biological Sciences, University of Trás-os-Montes and Alto Douro (UTAD), Quinta de Prados, Pavilhão 2, 5000-801 Vila Real, Portugal

<sup>c</sup> FCUP - Department of Biology, Faculty of Sciences, University of Porto (U. Porto), Rua do Campo Alegre s/n, 4169-007 Porto, Portugal

<sup>d</sup> Department of Analytical Chemistry, Nutrition and Food Sciences, IAQBUS - Institute of Research on Chemical and Biological Analysis, Universidade de Santiago de Compostela, Constantino Candeira S/N, 15782 Santiago de Compostela, Spain

<sup>e</sup> Inov4Agro –Institute for Innovation, Capacity Building and Sustainability of Agri-food Production, Portugal

**Number of pages: 13**

**Number of sections: 8**

**Number of figures: 3**

**Number of tables: 2**

## **Material and methods**

### **Section S1. Ethical review**

The bioassay was carried out at *Biotério de Organismos Aquáticos* (BOGA) facilities, at the Interdisciplinary Centre of Marine and Environmental Research (CIIMAR, Matosinhos, Portugal) in compliance with the European Directive 2010/63/EU, on the protection of animals used for scientific purposes and with the Portuguese Decreto-Lei 113/2013. The research project has received approval for research ethics from Animal Welfare and Ethics body (ORBEA – CIIMAR).

### **Section S2. F<sub>0</sub> reproductive trials after 4 months of MET exposure**

First, reproductive success was tested at 4 mpf using a tank breeding approach (tanks holding a number of males and females that replicate the treatment sex ratio). In the afternoon, before the beginning of the trials, aquaria from each treatment were divided in two separate sections in which a suspended cage with a net bottom covered with marbles was fixed; males and females were distributed through the cages (four reproductive units per treatment, n=4). A total of 12 reproductive events were performed for each treatment. Over the course of 6 days, 1-1.5 h after the beginning of the light period, breeding fish were removed and the eggs collected, cleaned, and conserved in 70% ethanol for subsequent counting. Reproductive success was assessed through the evaluation of two endpoints: fecundity (number of eggs per female per day) and percentage of fertilization (% of fertilized eggs per female per day). Unfertilized eggs were grouped with non-viable and un-activated eggs to determine the fertilization rate.

Furthermore, in order to determine whether the potential changes in reproductive success were due to paternal or maternal exposure to MET, a second reproductive study was conducted one week after the first reproductive trial, i.e. 4.25 mpf, using a pairwise cross breeding approach

(one male X one female) with fish from the highest MET concentration (13 000 ng/L nominal concentration) and control. Ten different couples per combination were used for this reproductive study (n=10). Briefly, zebrafish couples were placed in breeding chambers with net bottom covered with marbles, inside aquaria filled with clean dechlorinated water. Three combinations of couples were made: (1) both male and female from the control group; and two crossed reproductions, (2) a MET exposed male with a control female; and (3) a MET exposed female with a control male. Once embryos were collected, fecundity and fertilization rate were analyzed as described above.

### **Section S3. Embryogenesis studies in F<sub>0</sub> and F<sub>1</sub> generations**

After reproduction, newly fertilized eggs were collected and cleaned in order to initiate the F<sub>0</sub> and F<sub>1</sub> 96 hpf embryo assays, that were replicated four independent times. Briefly, 20 embryos from each treatment, with approximately 1.5 hpf, were randomly distributed in 24-well plates (one egg per well), filled with 2 mL of exposure medium, i.e., 390 to 14 423 ng/L of MET or dechlorinated water (control) in F<sub>0</sub> 96 hpf embryo assays; and MET-free dechlorinated water in F<sub>1</sub> 96 hpf embryo assay. The 24-well plates were randomly placed in an incubator and maintained at 28 ± 0.5 °C with a 14:10 (light:dark) photoperiod for 96 h, to mimic the chronic assay development conditions. Every 24 h, embryo mortality was checked, and the exposure medium renewed. At the end of each assay (96h), embryos were checked for morphological abnormalities on the head, tail, eyes and yolk-sac, as well as screened for oedemas, abnormal cell growth, and developmental arrest (which was only compared to the control group, as the assay temperature did not match the one from the FET Test 236<sup>1</sup>).

Additionally, total larvae length of the F<sub>0</sub> and F<sub>1</sub> generations (n = 40, 10 larvae per replicate) was measured at 96 hpf under an inverted microscope (Nikon Eclipse TS100), coupled with a digital camera Nikon D5 – Fi2.

#### **Section S4. Analytical quantification of MET**

Actual MET concentrations were determined three times during the experiment, to assure that concentrations were within the expected range. Samples were collected (1) one week after the beginning of exposure, (2) in the middle of the study, i.e., 4 mpf, and (3) one week before the end. At each time-point, two bulk samples from each treatment replicates were collected and stored at -20 °C until quantification.

Metformin determination in water samples was performed by Liquid Chromatography - Tandem Mass Spectrometry (LC-MS/MS) with an Acquity UPLC® liquid chromatography system from Waters (Milford, MA, USA). A sample volume of 45 µL was directly injected into an Acclaim Trinity P1 column (50 mm × 2.1 mm, 3 µm particle size) supplied by Thermo Fisher Scientific (Waltham, MA, USA) maintained at a constant temperature of 35 °C and using a 0.2 mL/min flow rate. The mobile phases consisted of (A) ultrapure water with 2% of acetonitrile and 2mM ammonium acetate at pH 5.5 and (B) acetonitrile with 20% of ultrapure water and 20 mM ammonium acetate at pH 5.5. The gradient was applied as follows: 0–2 min, 0% B; 2–10 min, linear gradient to 100% B; 10–15 min, 100% B and finally 15–20 min, 0% B<sup>2</sup>. The system was interfaced to a XEVO TQD® triple quadrupole mass spectrometer equipped with an electrospray interface (ESI). Nitrogen was used as a nebulizing and drying gas and Argon was used as collision gas. Metformin was determined in the electrospray positive polarity and multiple-reaction monitoring (MRM) mode of acquisition. Two MRM transitions were used: m/z 130 to m/z 60 as quantification transition and m/z 130 to m/z 71 as qualification transition. Under these chromatographic conditions, the retention time of metformin was 8.1 minutes. The method assured quantification limits (LOQ) of 10 ng/L. Quantification was performed by matrix matched calibration using standards prepared in dechlorinated system water in the 0.01-200 ng/mL range (which was checked to be linear, R<sup>2</sup>=0.9992). Repeatability of the determination was checked in

terms of relative standard deviation (RSD) at 0.5, 5 and 50 ng/mL levels and the values were lower than 10% in all cases.

Table S1 summarizes the actual concentrations of MET measured throughout the assay in each treatment at the three sampling points. MET was never detected in the control group. In most cases, the detected MET concentrations were higher than nominal ones, except for T3 13 000 ng/L treatment where the MET level decreased. Due to technical constraints, the water samples collected at the third sampling point from the 361 ng/L MET were lost and the actual concentration of MET could not be determined. The concentration variations were slightly out of the expected range, presenting an average deviation of 28.8 % from the nominal concentrations. Since MET is not metabolized in vertebrates, being released in its native form, it is possible that the variation in concentrations here observed is a result of MET accumulation in the aquaria throughout the 9-month exposure assay.

**Table S1.** Nominal and measured concentrations of MET in water samples collected through the duration of the bioassay, from each treatment. Data is expressed as mean  $\pm$  standard error (n = 2 replicates per sampling time). T<sub>1</sub> – first sampling time; T<sub>2</sub> – second sampling time; T<sub>3</sub> – third sampling time.

	Control	MET 361 ng/L <sup>a</sup>	MET 2 166 ng/L <sup>a</sup>	MET 13 000 ng/L <sup>a</sup>
T <sub>1</sub>	N.D. <sup>b</sup>	437.5 $\pm$ 62.90	2 410.5 $\pm$ 18.10	18 796.7 $\pm$ 186.00
T <sub>2</sub>	N.D. <sup>b</sup>	342.5 $\pm$ 19.00	2 767.0 $\pm$ 368.40	15 757.0 $\pm$ 1 182.40
T <sub>3</sub>	N.D. <sup>b</sup>	N.A. <sup>c</sup>	3 610.6 $\pm$ 1 256.30	8 718.0 $\pm$ 1 747.60

<sup>a</sup> – nominal concentrations; <sup>b</sup> – not detected; <sup>c</sup> – not analyzed

### Section S5. qRT-PCR primer design

Specific primers for qRT-PCR gene expression analysis of *vtg1*, *vtg2* and *rpl13* were designed using the Primer designing tool “Primer – BLAST” (NCBI) and Beacon Designer (Premier Biosoft International). To confirm the specificity of each primer, amplification products were run by 1% agarose gel electrophoresis and resulting bands were purified with GelPure (NzyTech), following

the manufacturers' protocol. Purified bands were then sequenced at GATC (Eurofins Genomics) and sequencing results were analyzed with the BLAST tool from NCBI in order to confirm the amplified sequence (Table S2).

**Table S2.** Primer sequences, forward (F) and reverse (R), and parameters used in the qRT-PCR for gene expression quantification in the liver (*vtg1* and *vtg2*) of 9-month *D. rerio* from control and MET treatments

Gene	Accession number	Sequence (5' – 3')	Expected band size (bp)	Combined annealing and extension temperature (°C)	Average efficiency (%)
<i>vtg1</i>	NM_001044897.3	F: CGCTGTTCCCATCAATCCAG	183	60	97
		R: TTGCAGTACAGCAGTGGTCTAA			
<i>vtg2</i>	NM_001044913.1	F: TACTCCTCCGTTGTTGGTGC	192	58	95
		R: AGCTTGATGAAGGCAGTGT			
<i>rpl13</i>	NM_198143.1	F: GCTGAAGGAATACCGCACCA	109	60	98
		R: TCCAGTAAGCTGTGTTGCCAT			

## Section S6. Fluorescence based quantitative real-time PCR (qRT-PCR) analysis

For each treatment, cDNA was synthesized from 1 µg of extracted RNA using the iScript™ cDNA Synthesis Kit (Bio-Rad). Each cDNA sample (n=8 per treatment and sex) was diluted by 1/5-fold and amplified with NZYSpeedy qPCR Green Master Mix (2x) (NZYTech) on a Mastercycler ep realplex system (Eppendorf), following the manufacturer instructions. A two-step qRT-PCR was performed as follows: initial denaturation at 95 °C (2 min), followed by 40 cycles of denaturation at 95 °C (15 s) and combined annealing and extension at 58 – 62 °C, depending on primer set (25 s) (Table S2). A melting curve was generated in each run to confirm the specificity of the reactions. Relative changes in the transcription abundance of target genes were normalized to the housekeeping gene (*rpl13*) expression and calculated using the  $2^{-\Delta\Delta Ct}$  analysis method<sup>3</sup>.

## **Section S7. Liver RNA-seq analysis**

In the RNA-seq analysis commercially obtained at Novogene (United Kingdom), RNA samples were subjected to a primary quality control. Integrity of test samples was evaluated in an Agilent 2100 Bioanalyzer system using the RNA Nano 6000 Assay Kit (Agilent Technologies, USA). Samples were shown to have an average RIN (RNA integrity number) of 9.8 and, as such, were used for library construction and sequencing.

Sequencing libraries were generated using the Novogene NGS RNA Library Prep Set Kit according to the manufacturer protocol. Briefly, poly-T oligo attached magnetic beads were used to isolate mRNA from total RNA, which was used as initial input material, and rRNA was removed using the Ribo-Zero Kit (Illumina, USA). mRNA was then fragmented with divalent cations under elevated temperatures in First Strand Synthesis Reaction Buffer (5x).. The first strand of cDNA was synthesized using random hexamer primer and M-MuLV Reverse Transcriptase (RNase H-), followed by second-strand synthesis using RNase H and DNA polymerase I. Remaining overhangs were then converted into blunt ends using polymerase/exonuclease activities. After adenylation of 3' ends of DNA fragments, adaptors with hairpin loop structure were ligated to prepare for hybridization. Second strands were enzymatically removed and resulting cDNA fragments were purified using the AMPure XP system (Beckman Coulter, USA) to select fragments of approximately 370~420 bp in length. Finally, a PCR was performed using Phusion High-Fidelity DNA polymerase (Thermo Fisher Scientific, USA), universal PCR primers and Index primers were used to attribute sequences to each sample. PCR products were then purified (AMPure XP system) and the cDNA library quality was checked with Qubit 2.0 fluorometer (Thermo Fisher Scientific, USA) and real-time PCR for quantification and Agilent Bioanalyzer 2100 system for quality assessment.

Index coded samples were clustered with a cBot Cluster Generation System, using TruSeq PE Cluster Kit V3-cBot-HS (Illumina, USA) according to manufacturer instructions. After clustering,


resulting libraries were sequenced on an Illumina Novaseq 6000 platform, generating 150 bp paired-end reads (an average 35 million pair-end reads per sample). Raw reads were submitted to NCBI SRA database under the BioProject number PRJNA906165.

Raw reads obtained from sequencing were processed through in house perl scripts (Novogene, UK). Through this process, clean reads were obtained by removing sequences containing adapters and/or poly-N above 10 % and low quality reads, i.e. reads with Qscore of over 50% bases below a score of 5, were also removed from raw data. GC content, Q20 and Q30 of clean data were also calculated. Further analyses were performed on clean and high quality data.


Index of *D. rerio* reference genome (GRCz11) was built using Hisat2 v2.0.5 and paired-end clean reads were aligned to the reference genome using Hisat2. Quantification of reads mapped to each gene was performed using featureCounts v1.5.0-p3 and FPKM (Fragments per kilo base of transcript per million mapped fragments) of each gene was calculated based on gene length and the amount of reads mapped to that gene.

Differential expression analysis was carried out using DESeq2 R package v1.20.0 <sup>4</sup>. The Benjamini & Hotchberg method <sup>5</sup> was used to correct resulting p-values, in order to eliminate the False Discovery Rate (FDR). Differentially expressed genes (DEGs) were set at  $\text{Log}_2(\text{FoldChange}) > 0$  and  $\text{padj (FDR p-value)} < 0.05$  and can be observed in Tables S3 and S4. Gene Ontology (GO) enrichment analysis of DEGs was determined using ShinyGO v0.76.3 <sup>6</sup>. GO terms with  $\text{padj} < 0.1$  were considered significantly enriched by DEGs (Tables S7 and S8). Hepatic differently expressed genes involved in steroid hormone biosynthesis, reproductive processes and energy/lipid metabolism were selected from the overall data and a protein-protein interaction (PPI) analysis was performed with Cytoscape (v3.9.1) with the String plugin attached. As the analysis showed differential expression of genes typically associated with other tissues, their expression in liver tissues was confirmed through GeneCards ([www.genecards.org](http://www.genecards.org)) and ZFIN (<https://zfin.org>) platforms.

## Results



**Figure S1.** Zebrafish 2 hpf eggs preserved in 75 % ethanol - 4× magnification. A – fertilized egg; b – unfertilized egg; c – un-activated egg.




**Figure S2.** Hierarchical clustering heatmap depicting the patterns of gene transcription between pool samples of F<sub>0</sub> control and 14 423 ng/L MET treatment, in male and female *D. rerio* after a 9-month exposure to MET. FCtrl – Female control; Fmet – 14 423 ng/L MET exposed Female; MCtrl – Male control; Mmet - 14 423 ng/L MET exposed Male.

## Section S8. Male Gene Ontology (GO) and Protein-Protein Interaction

The Gene Ontology (GO) enrichment analysis revealed a total of 14 biological processes (BP) significantly enriched ( $p_{adj} < 0.1$ ) and upregulated, all involved in energy/lipid metabolism (Table S7). Of those, the ones with bigger statistical differences were “Fatty acid b-oxidation” and “Carboxylic acid metabolic process”, both expected as part of MET MoA. 15 BP were also found to be significantly enriched and downregulated. Of those, 2 are involved in steroid hormone biosynthesis, i.e. “Steroid hormone biosynthesis” and “C21-steroid hormone metabolic process”, while the remaining 13 are involved in reproductive processes (Table S7).

The Protein-Protein Interaction (PPI) analysis performed for males, several interesting network of interaction between genes involved in energy/lipid metabolism, steroid hormone biosynthesis and reproduction were identified (Figure S3). The analysis revealed that energy metabolism and reproduction interact through several genes, such as *ak7a*, *ak7b*, *dnah1* and *cfap43*. As expected, steroid hormone biosynthesis related genes (*cyp11c1*, *cyp17a1* and *star*) were shown to have strong interactions with *amh*, *star* and *dmt1*, i.e., genes involved in reproduction, more specifically spermatogenesis.



**Figure S3.** Protein-protein Interaction (PPI) of DEGs involved in steroid hormone biosynthesis (yellow), reproduction (orange) and lipid/energy metabolism (green) in the liver of *F0 D. rerio* males exposed to 14 423 ng/L of MET. Thicker lines indicate stronger interactions (power from 0.7 to 1).

## References

- (1) OECD. Test No. 236: Fish Embryo Acute Toxicity (FET) Test. *OECD Guidel. Test. Chem. Sect. 2, OECD Publ.* **2013**, No. July, 1–22.  
<https://doi.org/10.1787/9789264203709-en>.
- (2) Montes, R.; Rodil, R.; Cela, R.; Quintana, J. B. Determination of Persistent and Mobile Organic Contaminants (PMOCs) in Water by Mixed-Mode Liquid Chromatography-Tandem Mass Spectrometry. *Anal. Chem.* **2019**, *91* (8), 5176–5183.  
<https://doi.org/10.1021/acs.analchem.8b05792>.
- (3) Livak, K. J.; Schmittgen, T. D. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the  $2^{-\Delta\Delta C(T)}$  Method. *Methods* **2001**, *25* (4), 402–408. <https://doi.org/10.1006/meth.2001.1262>.
- (4) Love, M. I.; Huber, W.; Anders, S. Moderated Estimation of Fold Change and Dispersion for RNA-Seq Data with DESeq2. *Genome Biol.* **2014**, *15* (12), 1–21.  
<https://doi.org/10.1186/S13059-014-0550-8/FIGURES/9>.
- (5) Benjamini, Y.; Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J. R. Stat. Soc. Ser. B* **1995**, *57* (1), 289–300.  
<https://doi.org/10.1111/J.2517-6161.1995.TB02031.X>.
- (6) Ge, S. X.; Jung, D.; Jung, D.; Yao, R. ShinyGO: A Graphical Gene-Set Enrichment Tool for Animals and Plants. *Bioinformatics* **2020**, *36* (8), 2628–2629.  
<https://doi.org/10.1093/BIOINFORMATICS/BTZ931>.